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ABSTRACT 
Metabolic engineering approaches to biosynthesize terpenoids in Saccharomyces 
cerevisiae 
by 
Caroline V. McNeil 
Terpenoids are the largest class of natural products and are typically isolated from 
natural sources. However, heterologous expression of terpene synthases in microbial 
hosts such as E. coli or Saccharomyces cerevisiae has become an attractive alternative. S. 
cerevisiae has an intact sterol biosynthetic pathway, and many of the intermediates also 
serve as precursors for terpene synthases. Metabolic engineering efforts focus on 
optimizing product yields through increasing carbon flux through the desired pathway, 
removing competing enzymes, or altering enzymatic activity. 
This work describes the metabolic engineering of S. cerevisiae to enhance terpene 
production by exploiting these three approaches. Diterpene synthases were expressed in a 
yeast strain previously reported to accumulate the diterpene precursor geranylgeranyl 
pyrophosphate (GGPP). The strains produced milligram amounts of GGPP hydrolysis 
products geranylgeraniol and geranyllinalool, as well as the GGPP cyclization products 
ew^-copalyl pyrophosphate, ent-kauvene, and abietadiene. Because diterpene production is 
limited by transit peptides targeting diterpene synthases into plastids, protein expression 
was increased by co-expressing a chloroplast processing enzyme in two different 
diterpene-producing strains. The in vivo-generated mature diterpene synthases functioned 
more effectively, thereby increasing cyclization yield. 
This thesis also describes a new method for controlling farnesyl pyrophosphate 
(FPP) hydrolysis product profile by adjusting media pH. Hydrolysis was found to be 
partially controlled by a phosphatase DPP1, however a majority of FPP hydrolysis is non-
enzymatic. In a squalene synthase deletion strain, FPP accumulates and hydrolyzes 
readily to farnesol and nerolidol, and the ratios of these products are determined by the 
pH of the media. 
Finally, a yeast strain was constructed to increase production of the 30-carbon 
triterpene precursors oxidosqualene (OS) and dioxidosqualene (DOS) by over-expressing 
the sterol biosynthesis rate-limiting enzyme 3-hydroxy-3-methylglutaryl CoA reductase 
(HMG1) in a lanosterol synthase deletion background. This strain accumulated twenty 
times more OS and DOS than the strain with only the native HMG1. Over-expression of 
squalene epoxidase (ERG1) in a lanosterol synthase background greatly enhanced the 
levels of DOS compared to OS. 
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Chapter 1 
Background and Introduction 
The largest class of natural products is the terpenoids, a diverse group of 
compounds with many different functions in plants, fungi, and animals. Terpenoids can 
be divided into two main groups - primary metabolites and secondary metabolites. 
Within the primary metabolites are the sterols, such as cholesterol, which make up 
cellular membranes, and hormones, such as estrogen, testosterone, or the plant hormones 
gibberellins. The majority of terpenoid structural diversity arises from secondary 
metabolites isolated primarily from plants. These compounds serve a variety of functions 
in plants, including defending against insects and counteracting stress situations or 
infections. In addition to being utilized by plants, a large number of terpenes also have 
commercial applications. These include medicinal applications such as the 
chemotherapeutic agent paclitaxel (trade name Taxol®) and the anti-malarial drug 
artemisinin, or fragrance applications such as patchouli or nootkatone, two components in 
many perfumes. 
Terpenes are derived from the five-carbon isoprene unit and differ in their number 
of carbons, size and number of rings, and functionality. Though typically these 
compounds are derived from the mevalonate pathway, beginning with acetyl-CoA to the 
5-carbon precursor isopentenyl pyrophosphate (IPP), a mevalonate-independent pathway 
was discovered in 1993 in bacteria, green alga, and higher plants.1"3 The non-mevalonate 
pathway begins with glyceraldehyde-3-phosphate and pyruvate and ultimately forms IPP 
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and later famesyl pyrophosphate (FPP). This thesis focuses on the mevalonate pathway, 
so the non-mevalonate pathway will not be discussed in depth. 
The mevalonate pathway generates the necessary substrates for terpene 
production, including sterol biosynthesis. Plants, fungi, and mammals all produce sterols, 
and their biosynthetic pathways are identical up until production of the 30-carbon 
oxidosqualene (OS). The pathways diverge after this point to form the membrane sterols 
required by each organism. Plants cyclize OS to cycloartenol which is further 
metabolized to sitosterol and stigmasterol. Fungi and mammals cyclize OS to lanosterol, 
and the pathways then diverge to form cholesterol in mammals and ergosterol in fungi. 
This thesis focuses on manipulation of the sterol biosynthetic pathway of Saccharomyces 
cerevisiae for biosynthesis of many different terpenoids. 
S. cerevisiae sterol biosynthetic pathway 
Sterol biosynthesis starts with the conversion of acetyl-CoA to mevalonate in a 
two-step enzymatic process (Figure 1.1). First, two molecules of acetyl-CoA condense to 
form acetoacetyl-CoA via a Claisen condensation mechanism, catalyzed by acetoacetyl-
CoA thiolase (ERG10).4'5 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
synthase (HMGS, ERG13)4'6 catalyzes an aldol condensation of another molecule of 
acetyl-CoA with acetoacetyl-CoA to yield HMG-CoA. 
3 
O JERGIO^ O O ERG13, J v PH& 
/ % - C o A £ _ _ . ^ ^ S - C o A 5 o r n A H O ^ ^ ^ S - C o A 
Acetyl-CoA Acetoacetyl-CoA HMG-CoA 
Figure 1.1. The first two steps of the sterol biosynthetic pathway involve condensation of 
three molecules of acetyl-CoA to form HMG-CoA. The reactions are catalyzed by 
ERGlOandERGB. 
In yeast with low levels of ergosterol produced, activities of both ERG 10 and 
ERG 13 increased substantially, while enzymatic activity is much lower when excess 
ergosterol is present.7 As ERG 10 activity increased, ERG 13 activity increased at the 
same rate, suggesting ERG13 activity is dependent on that of ERG10 and that the two 
enzymes are regulated by similar mechanisms. 
HMG-CoA reductase (HMGR) is the rate-limiting enzyme in sterol biosynthesis, 
catalyzing the formation of mevalonic acid from HMG-CoA (Figure 1.2).9 S. cerevisiae 
encodes two genes HMG1 and HMG2 that both possess HMGR activity.10 The N-termini 
(339 amino acids) of these two enzymes are anchored to the endoplasmic reticulum (ER), 
while the C-termini reach into the cytoplasm and contain the enzyme active sites.11 
9 v0H<u HMGR, 9 v P H 
HMG-CoA Mevalonic acid 
Figure 1.2. Reduction of HMG-CoA to mevalonic acid by HMG-CoA reductase. 
These two enzymes are highly regulated by several factors, including feedback 
control12'13 and HMGR degradation.14 HMG1 was found to be fairly stable while HMG2 
was quickly degraded.14 When ERG10, ERG13, or even HMGR activity was repressed, 
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production of the HMGR protein was increased, suggesting that an intermediate 
downstream of HMGR was involved in feedback regulation. 
HMG1 and HMG2 are ER-bound proteins and therefore subject to ER 
degradation. Degradation of these two enzymes is controlled by flux within the 
mevalonate pathway; increased degradation was observed when flux increased and less 
degradation was recorded as flux decreased.14 HMG2 is ubiquitinated by the UBC7 
enzyme, with ubiquitination dependent on flux through the mevalonate pathway, and this 
mechanism is what regulates HMG2 stability and degradation in yeast.15 FPP is the 
feedback signal that controls ubiquitination and therefore degradation of HMG2.15'16 
Overexpression of HMG1 in yeast led to formation of karmellae, stacked 
membranes situated about the nucleus, of the endoplasmic reticulum whereas 
overexpression of HMG2 did not produce these structures.17 A 552-residue truncation 
(trHMGl) was constructed that contained only the catalytically active C-terminal region 
by removing the N-terminal membrane-spanning domain.18 This modification formed a 
soluble protein and removed transcriptional regulation. Overexpression of this trHMGl 
dramatically increased squalene accumulation but only modest improvement in sterol 
production was observed.18'19 This result indicated that another rate-limiting enzyme must 
exist after squalene biosynthesis. 
Mevalonic acid, or its deprotonated form mevalonate, is converted to the 5-carbon 
terpene precursor IPP in three ATP-dependent steps (Figure 1.3). First, mevalonate is 
phosphorylated, catalyzed by mevalonate-5-phosphotransferase (ERG12), to yield 
phosphomevalonate.20 Mevalonate-5-pyrophosphate forms from a second 
phosphorylation catalyzed by phosphomevalonate kinase (ERG8).20,21 Finally, 
mevalonate-5-pyrophosphate is decarboxylated by pyrophosphomevalonate 
decarboxylase (ERG19), yielding IPP.22,23 
ft V ° H ERG12, ft V ° H ^ 9 ERG8, } V ° H ERG19- J 
O" Mevalonate-
Mevalonate Phosphomevalonate 5-pyrophosphate IPP 
Figure 1.3. Conversion of mevalonate to IPP. Two phosphorylations and a 
decarboxylation reaction yield the 5-carbon isoprene unit. 
IPP is utilized in chain elongation to form the sterol and terpene precursors 
geranyl pyrophosphate (GPP), FPP, and geranylgeranyl pyrophosphate (GGPP). To form 
GPP, a molecule of IPP condenses with a molecule of its isomer dimethylallyl 
pyrophosphate (DMAPP). Isomerization of IPP to DMAPP is carried out by IPP 
isomerase (IDI1),24 forming the more energetically favorable internal trisubstituted 
double bond (Figure 1.4). 
IDI1 
Opp ' - ^ - -0PP 
IPP DMAPP 
Figure 1.4. Isomerization of IPP to DMAPP, catalyzed by IPP isomerase. 
The next three steps in sterol biosynthesis involve a family of enzymes known as 
prenyltransferases. These enzymes catalyze condensations with IPP, DMAPP, and other 
polyprenyl intermediates in either head-to-tail or head-to-head condensation reactions. 
These enzymes are involved in chain-length elongation and play a vital role in sterol, and 
terpenoid, biosynthesis. Prenyltransferases contain a conserved DDXXD motif25 to bind 
the allylic substrates,26 and prenyltransferases such as FPP synthase and GGPP synthase 
also possess two aspartate-rich regions. 
FPP synthase27 (ERG20) catalyzes two separate condensation reactions in S. 
cerevisiae. First, ERG20 catalyzes the head-to-tail condensation of one molecule of 
DMAPP and one molecule of IPP to form the 10-carbon GPP. GPP does not accumulate 
but instead condenses with another molecule of IPP to form FPP. 
OPP 
I
 + I . ERG20> r ^ ^ < ^ 
IPP DMAPP I GPP 
Figure 1.5. Condensation to GPP and FPP by FPP synthase (ERG20). 
Wild-type S. cerevisiae does not produce geraniol or farnesol, hydrolysis 
products of GPP and FPP, respectively. Through a series of mutagenesis experiments two 
yeast mutants were discovered that lacked squalene synthase activity. One of these 
mutants secreted farnesol into the medium, while the other mutant secreted both farnesol 
and geraniol.28 It was determined that an ERG20 mutant Lysl97Glu led to formation of 
geraniol and linalool into the media, suggesting that this residue was vital for FPP 
90 
synthase activity. Blanchard and Karst proposed that the lysine residue was important 
for substrate binding, and replacing this residue with a glutamic acid residue decreased 
the affinity for GPP and therefore reduced chain-length elongation. The catalysis to yield 
FPP was not completely eradicated, leading to formation of farnesol in addition to the 
monoterpene alcohols. 
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Mutagenesis experiments undertaken on avian FPP synthase revealed that two 
other mutations, AlalHTrp and Asnl44Trp, led to smaller active site pockets that no 
longer accepted GPP as substrate.30 These mutants only accepted DMAPP and IPP, 
therefore functioning only as GPP synthases. 
FPP is a branch point in the pathway and is utilized in several biosynthetic 
pathways. In addition to sterol biosynthesis, FPP is involved in protein prenylation and 
the formation of GGPP, dolichols, and ubiquinones. 
Because FPP is the substrate for multiple pathways in yeast, ERG20 is a highly-
regulated enzyme. To determine the effect of ERG20 on sterol biosynthesis, however, the 
enzyme cannot be completely deleted. Therefore mutagenesis experiments to lower FPP 
•2 1 
synthase activity have been undertaken. Lowering FPP synthase activity 42% 
(compared to wild-type) did not cause a significant drop in ergosterol biosynthesis, but 
decreasing activity to 20% reduced ergosterol production by 50%. When enzymatic 
activity was lowered further, ergosterol biosynthesis did not change appreciably, most 
likely because FPP was being diverted from other pathways to sustain sterol metabolism 
for growth. Because of this diversion, the yeast did not grow as quickly or as strongly as 
observed in earlier strains.31 
Alternatively, overexpression of FPP synthase led to a 6-fold increase in FPP 
synthase activity and a 20% increase in HMGR activity.32 The overexpression also 
increased dolichol and ergosterol production. Under aerobic conditions excess FPP is 
diverted to dolichol production, and these results suggest that ERG20 serves a role in 
regulating FPP to either squalene or dolichol production. Any ergosterol surplus can be 
stored as acyl esters.33 
8 
Yeast utilizes GGPP primarily as the substrate for protein prenylation. GGPP 
synthase (BTS1) catalyzes the condensation of FPP with another molecule of IPP to form 
the 20-carbon molecule.34 Because demand for GGPP in yeast is modest, little GGPP 
accumulates in wild-type S. cerevisiae?5 
OPP 
FPP N GGPP 
Figure 1.6. FPP and IPP condense to form GGPP. 
Protein prenylation is catalyzed by three main families of enzymes, protein 
farnesyltransferase (PFTase) and two classes of protein geranylgeranyltransferase 
(PGGTasel and PGGTasell).36 PFTase and PGGTasel catalyze the alkylation of a 
cysteine residue within a CAAX motif (A is an aliphatic amino acid) at the C-terminus of 
various proteins. For farnesylation to occur, X must be Ala, Met, Gin, or Ser), while the 
geranylgeranyl moiety is added when X is Leu, Asn, or sometimes Phe.37 The 
farnesylated or geranylgeranylated proteins have increased affinity for membranes, and 
the alkylation aids in membrane recognition.36 
The final condensation reaction involves squalene synthase (ERG9) catalyzing the 
condensation of two FPP molecules to form the 30-carbon squalene (Figure 1.7). ' This 
is the first committed step in sterol biosynthesis and requires magnesium ions and either 
NADH or NADPH for catalysis to occur. Unlike the FPP and GGPP synthases, squalene 
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synthase catalyzes a head-to-head condensation by first dimerizing FPP to presqualene 
pyrophosphate and then promoting a reductive elimination to form squalene.40 
FPP presqualene pyrophosphate squalene 
Figure 1.7. ERG9 catalyzes the condensation of 2 FPP molecules to form squalene. 
Presqualene pyrophosphate forms as an intermediate. 
Yeast strains deficient in ERG9 activity accumulate FPP41'42 and the FPP 
derivative farnesol, a hydrolysis product secreted into the medium.28 Dolichol production 
also increased. ERG9 thus regulates FPP flux through sterol or dolichol biosynthesis. 
Squalene epoxidase (ERG1) oxidizes squalene to (35)-oxidosqualene43,44 in a 
FAD- and NADPH-dependent reaction (Figure 1.8).45 This is the first step of the pathway 
requiring molecular oxygen,45'46 and strains grown in anaerobic conditions to block 
squalene epoxidase activity were found to accumulate squalene and no sterols.47 ERG1 is 
under transcriptional regulation, with enzymatic activity dependent on ergosterol and 
lanosterol levels,48 and the highest enzymatic activity was reported in strains deficient in 
lanosterol synthase activity.49 When lanosterol biosynthesis is limited, OS can re-enter 
the ERG1 active site and form (35, 235)-dioxidosqualene (DOS) from epoxidation at the 
distal terminus.50 
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ERG1 
squalene oxidosqualene dioxidosqualene 
Figure 1.8. Epoxidation of squalene to form OS. OS can re-enter the ERG1 active site, 
yielding DOS. 
Wild-type yeast grown in aerobic conditions accumulates almost no OS, which is 
efficiently cyclized to lanosterol. Overexpression of ERG 1 in a trHMGl overexpression 
background increased lanosterol production almost 4-fold and overall sterol yields nearly 
2-fold.51 Squalene accumulation simultaneously decreased 50%. OS did not accumulate 
in this strain; lanosterol and its metabolites were still the only products observed. 
Lanosterol synthase (ERG7) cyclizes OS to the tetracyclic lanosterol through a 
cationic mechanism (Figure 1.9).52 Lanosterol synthase can also accept dioxidosqualene 
to form epoxylanosterol,53'54 a precursor for oxysterols that help regulate sterol 
biosynthesis.55 
A series of 11 enzymes modify the lanosterol skeleton to the membrane 
ergosterol. First, lanosterol C-14 demethylase (ERG11) removes the C-14 methyl group 
from lanosterol in a P45o-dependent oxidation reaction.56 The new double formed by 
ERG 11 is reduced by A14-reductase (ERG24) to give 4,4-dimethyl zymosterol in an 
NADPH-dependent reaction.57'58 A series of enzymatic reactions catalyzed by ERG25,59 
ERG26,60 ERG27,61 and ERG2862 remove the two methyl groups at C-4, yielding 
zymosterol. C24-Methyltransferase (ERG6),63 an isomerase (ERG2),64'65 two desaturases 
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(ERG3 and ERG5),66'67 and a reductase (ERG4)68 act in succession to form the final 
ergosterol product. 
oxidosqualene lanosterol ergosterol 
Figure 1.9. ERG7 catalyzes the cyclization of OS to lanosterol. Further modifications of 
lanosterol are carried out by 11 other enzymes to form ergosterol. 
Other S. cerevisiae enzymes aiding in terpenoid biosynthesis 
The UPC2 transcription factor is part of a superfamily of DNA binding proteins69 
70 
that help regulate processes in S. cerevisiae. A single point mutation, upc2-l, increased 
71 
sterol uptake 5-fold compared to wild-type yeast under aerobic conditions. The 
Gly888Glu mutant70 also led to an increase in carbon flux through the sterol biosynthetic 
77 
pathway, however the exact mechanism for this increase is still not understood. 
Without an intact sterol biosynthetic pathway, yeast needs to import sterols in 
order to survive. Because many steps in sterol biosynthesis require O2, anaerobically 
grown yeast must import sterol. However, S. cerevisiae grown under aerobic conditions 
does not normally import exogenous sterols, even when mutations or inhibitors prohibit 
sterol biosynthesis. Simple sterol biosynthesis mutants are consequently not viable under 
aerobic growth conditions. To overcome this obstacle, sterol biosynthetic mutants 
included a heme biosynthetic mutant, which mimics anaerobic conditions, allowing yeast 
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to utilize exogenous sterol. A HEM1 deletion has been reported in an ERG7 deletion 
TX 
strain that allowed import of sterols under aerobic conditions. 
As noted above, yeast without a functional squalene synthase accumulate the FPP 
hydrolysis product farnesol. This hydrolysis has been attributed to phosphatases in the 
yeast. Two phosphatases, diacylglycerol pyrophosphate phosphatase (DPP1)74 and lipid 
phosphate phosphatase (LPP1),75 have been implicated in isoprenoid pyrophosphate 
hydrolysis. Deletion of LPP1 led to 25% less hydrolysis activity against several 
substrates, including FPP and GGPP. DPP1 deletion showed a more dramatic reduction 
in hydrolysis activity, with 75% less activity recorded. The double deletion (IpplAdpplA) 
showed almost no hydrolytic activity remained.76 DPP1 showed strong hydrolysis 
activity against GGPP, with GGPP levels decreasing at the same levels geranylgeraniol (a 
GGPP hydrolysis product) increased. The double deletion strain showed a small amount 
of Mg2+-dependent activity remained, which suggested that another phosphatase could be 
present in yeast to hydrolyze isoprenoid pyrophosphates. Indeed, a soluble form of an 
alkaline phosphate from yeast converted FPP to farnesol in vitro.77 
Metabolic engineering for terpenoid production 
Extraction of terpenoids from their natural sources is the most direct route, 
however a large amount of material is necessary to obtain enough material for analysis or 
commercial applications. Total synthesis eliminates the need for natural sources but has 
limitations due to lengthy, complex reaction sequences and low yields. Additionally, 
hazardous reagents are often utilized, making many of these syntheses unhealthy for the 
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environment. An attractive alternative is heterologous expression of terpene synthases in 
plants or microbial hosts. 
Metabolic engineering of plants is a promising alternative to synthesis and 
extraction. As plants produce the majority of terpenoids found in nature, they already 
contain the necessary enzymes for precursor production. Work on transgenic plants to 
improve terpenoid production has focused on two main areas, increasing precursor 
availability and expressing foreign synthases or overexpressing native enzymes. 
However, metabolic engineering in plants is quite difficult because of poorer 
transformation efficiency, long generation times, insufficient understanding of the 
regulation of the biosynthetic pathways, and complexities that arise from the different 
subcellular locations of the plant enzymes. 
Other challenges arise from rerouting precursors away from the plant's primary 
metabolism. For example, phytoene synthase was overexpressed in tomatoes, and even 
though carotenoid production increased, plant growth was stunted.78 This stunting was 
attributed to diversion of the phytoene precursor GGPP from the biosynthesis of 
gibberellins, which are essential for plant growth. Similar results were reported when 
Besumbes et al. expressed taxadiene synthase, the diterpene synthase involved in 
paclitaxel biosynthesis, in Arabidopsis thaliana. Taxadiene yields were approximately 20 
ng/g plant, but plant growth was also stunted, and this phenotype was also attributed to a 
foreign enzyme affecting regulation of enzymes in isoprenoid biosynthesis. This 
amount of taxadiene shows the potential of this technology for terpene biosynthesis; 
however this method is still limited. 
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Microbial hosts utilized for terpenoid biosynthesis have demonstrated much 
higher titers than those reported in plants. Escherichia coli and Saccharomyces cerevisiae 
are two hosts widely reported to produce many classes of terpenes, including 
monoterpenes,80'81 sesquiterpenes,82"85 diterpenes,86'87 triterpenes, and carotenoids. There 
are several advantages to using E. coli or S. cerevisiae, including fast doubling times (1-2 
hours), well-known genetics, and ease of manipulation. E. coli has the disadvantage, 
however, of not having an endogenous sterol biosynthetic pathway, so many genes for 
terpene biosynthesis must be introduced into the strains. 
However, E. coli has the non-mevalonate pathway to produce other terpenoids 
necessary for growth. Manipulation of this pathway in combination with expression of 
several terpene synthases has led to increased levels of monoterpenes, sesquiterpenes, 
and diterpenes81 in vivo. However these yields have not been as substantial as those 
reported in yeast. 
S. cerevisiae, on the other hand, has an intact sterol pathway, producing the 
substrates necessary for terpene biosynthesis. To increase the amounts of intermediates, 
two main approaches are utilized. First, carbon flux is increased by overexpressing rate-
limiting enzymes such as trHMGl. Removing or repressing competing enzymes has also 
enhanced terpene yields, with combinations of the two manipulations demonstrating even 
higher yields. 
The 10-carbon monoterpenoids are derived from hydrolysis or cyclization of the 
precursor GPP and comprise a large number of flavors and fragrances. Further 
metabolism, such as oxidation, leads to compounds such as menthol and camphor. These 
compounds are produced mainly in plants, and engineering efforts in microbial hosts are 
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less common. S. cerevisiae does not naturally accumulate GPP and therefore does not 
produce monoterpenes. An S. cerevisiae mutant strain was previously reported to produce 
geraniol and linalool when an FPP synthase Lysl97Glu mutation was expressed.29 This 
mutant forms GPP preferentially over FPP. Geraniol synthase from Ocimum basilicum 
was expressed in wild-type and mutant S. cerevisiae (containing the FPP synthase 
mutant), and nearly 1 mg/L of geraniol and linalool were isolated from the mutant 
strain.80 
Metabolic engineering to increase sesquiterpene production in microbial hosts has 
made great strides, with levels increased dramatically compared to what was first 
reported. Sesquiterpenes are produced from cyclization or hydrolysis of FPP by 
sesquiterpene synthases to a wide variety of hydrocarbon skeletons. In wild-type S. 
cerevisiae FPP does not accumulate, as it serves as a precursor in multiple biosynthetic 
pathways. The sesquiterpene synthase epicedrol synthase was expressed in wild-type and 
engineered yeast, and little epicedrol was isolated from the medium.82 Overexpression of 
a soluble form of HMG1 (trHMGl) in a upc2-l background increased epicedrol yields 3-
fold in comparison to that observed in wild-type strains. Overexpression of FPP synthase 
did not significantly increase sesquiterpene yields. 
Repression of the competing enzyme squalene synthase (ERG9) dramatically 
increased yields of several cyclization products. A down-regulated ERG9, in combination 
with an overexpressed trHMGl and the upc2-l mutation, was utilized to increase 
artemisinic acid production in vivo. Amorphadiene synthase (the sesquiterpene synthase 
involved in artemisinin production), a P450 oxidase, and a P450 reductase were co-
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expressed in this yeast strain, and up to 115 mg/L of artemisinic acid were produced in 
optimized culture conditions. 
Takahashi and coworkers also reported co-expression of a sesquiterpene synthase 
and a P450 oxidase in an engineered yeast strain to produce capsidiol yields over 50 
mg/L.84 This engineered strain included the overexpressed trHMGl and deleted ERG9, 
but the phosphatase DPP1 was also deleted to see if this would decrease FPP hydrolysis 
to farnesol. Though farnesol levels decreased in the dpplA strain, the manipulation did 
not significantly increase cyclized product yields. 
These results demonstrate the utility of S. cerevisiae for sesquiterpene production, 
as well as the potential for accumulating oxidized terpenoids in vivo. Introducing 
sesquiterpene synthases in combination with P450 oxidases has shown high efficiency 
turnover to produce compounds such as artemisinic acid or capsidiol. 
Diterpenoids, derived from the C-20 precursor GGPP, encompass a large class of 
natural products with diverse applications. Among these compounds are casbene, an 
antimicrobial and antifungal agent; paclitaxel, a drug used for breast cancer treatment; 
aphidocolin, an anti-viral agent; and e»/-kaurene, the biological precursor for gibberellin 
plant hormones. Metabolic engineering of strains for diterpene production has been 
explored less than sesquiterpene production; however a few trends have been discovered 
that increased diterpene yields significantly. 
The 20-carbon precursor GGPP is cyclized by a diterpene synthase to the final 
diterpene product or hydrolyzed to form geranylgeraniol or geranyllinalool. E. coli has 
been engineered to heterologously express several diterpene synthases, including Abies 
grandis abietadiene synthase,87 Ricinus communis casbene synthase,81 e«?-kaurene 
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synthase,81 and Taxus brevifolia taxadiene synthase,86 which catalyzes the first step in 
paclitaxel biosynthesis. In one instance, the E. coli l-deoxy-D-xylulose-5-phosphate 
synthase, a Haematococcus pluvialis IPP isomerase, and an E. coli FPP synthase carrying 
a mutation to produce GGPP were overexpressed in E. coli. Casbene synthase was 
Q 1 
expressed in this strain, and approximately 30 ug/L casbene was isolated. Despite the 
overexpression of several enzymes, the diterpene titers were rather modest. 
Wild-type S. cerevisiae produces little GGPP, as farnesyl pyrophosphate is 
diverted to other pathways. By overexpressing the yeast GGPP synthase BTS1 and a 
truncated HMG-CoA reductase, the amount of GGPP produced increased significantly. 
Eight genes from Taxus brevifolia involved in paclitaxel biosynthesis, including the 
Taxus GGPP synthase, were introduced into wild-type S. cerevisiae and produced 
milligram amounts of oxidized diterpenoids. This work demonstrates the potential of 
yeast for diterpene production, as much higher levels were observed than reported in E. 
coli. 
One limitation of diterpene biosynthesis in microbial hosts is that diterpene 
synthases contain transit peptides that target the proteins to plastids within the plant.90 
The transit peptides are cleaved once inside the organelle to yield the mature protein,91 
but E. coli and S. cerevisiae do not have the mechanisms to cleave these transit peptides. 
To overcome this, diterpene synthases have been manually truncated to remove putative 
transit peptides, and this has increased diterpene yields in both E. coli and yeast. ' 
To study triterpene biosynthesis, yeast hosts were constructed to accumulate OS, 
the precursor for triterpene synthases. Yeast preferentially cyclizes OS to lanosterol for 
use in sterol biosynthesis, so in order to accumulate OS, the competing enzyme ERG7 
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was deleted. This strain, SMY8,97 accumulates both OS and DOS and has allowed for 
characterization of numerous oxidosqualene cyclases.52'98"102 This strain has also aided in 
characterization of DOS cyclization products by oxidosqualene cyclases, leading to 
discovery of novel enzymatic activity and novel compounds.103 To improve yields, 
further work is necessary to increase accumulation of the OS precursor. As this thesis 
was being written, several strains engineered for triterpene biosynthesis were 
published.104 Kirby and coworkers first overexpressed trHMGl in wild-type yeast with 
Artemisia annua P-amyrin synthase, leading to an increase in squalene accumulation but 
not in p-amyrin yields. A combination of repressed ERG7 and trHMGl overexpression 
doubled P-amyrin production from 3 mg/L (wild-type) to 6 mg/L. 
Metabolic engineering of microbial hosts has become an important tool in the 
characterization and overproduction of a wide variety of terpenoids. Through a 
combination of increased metabolic flux and deletion of competing enzymes, the levels 
of terpenes produced in these engineered strains has increased dramatically, in some 
cases up to 30 mg/L of terpenes. Co-expression of terpene synthases and P45o-dependent 
oxidases has uncovered a wealth of new natural products, and this technology can be 
utilized to build libraries of potential medicines, perfumes, or other compounds with 
potential commercial value. Despite all the metabolic engineering work done thus far a 
great deal remains to be done to increase yields further. 
Summary 
The work presented here shows the utility of S. cerevisiae for terpenoid 
production. Manipulation of the sterol biosynthetic pathway allowed for increased 
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accumulation of several terpene substrates, including FPP, GGPP, OS, and DOS. First, a 
strain previously reported to accumulate the diterpene precursor GGPP was utilized to 
produce the gibberellin precursors enf-copalyl pyrophosphate and ewf-kaurene. To further 
increase diterpene yields, an Arabidopsis chloroplast processing enzyme was co-
expressed with the Abies grandis abietadiene synthase and with the Arabidopsis ent-
copalyl pyrophosphate synthase and e«f-kaurene synthase. These manipulations led to 
dramatic increases in diterpene production, as the signaling sequences were removed to 
solubilize the proteins, optimizing enzymatic activity. Additionally, S. cerevisiae was 
engineered to increase FPP accumulation for sesquiterpene production, resulting in high 
yields of the FPP hydrolysis products farnesol and nerolidol. In attempts to reduce 
hydrolysis, two phosphatases were deleted from the yeast and their effects were studied. 
Finally, triterpene substrate product profiles were influenced by overexpression of 
squalene epoxidase or the sterol rate-limiting enzyme trHMGl. These manipulations 
increased OS and DOS accumulation in yeast. 
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Chapter 2 
Production of gibberellin precursors in metabolically engineered yeast 
Introduction 
Diterpenoids are a large class of natural products that serve diverse functions 
within plants, such as defense chemicals against insect herbivory or infection or as 
primary metabolites such as gibberellins, hormones that regulate growth, development, 
and other processes within the plant.105 Many of the biological activities are adaptable for 
pharmaceutical purposes, and these diverse compounds have been extracted from plant 
sources for use as medicines such as paclitaxel, a chemotherapeutic from the Pacific yew 
tree,106 and casbene, an antimicrobial and antifungal agent isolated from castor 
beans.107'108 
However, extraction from natural sources has severe limitations, as large amounts 
of plants are needed to obtain sufficient amounts of material. Microbial hosts have 
become an attractive alternative for diterpene production and have been utilized to 
heterologously express diterpene synthases,86'89'94'109'110 the enzymes that cyclize the 20-
carbon precursor geranylgeranyl pyrophosphate (GGPP) into diterpene products. 
Results and Discussion 
To examine the utility of Saccharomyces cerevisiae for diterpene production, two 
genes from the Arabidopsis thaliana gibberellin biosynthetic pathway were expressed in 
a metabolically engineered yeast strain EHY18. EHY18 was previously developed in our 
lab to increase GGPP accumulation in vivo.35'111 Yeast more readily converts the C-15 
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famesyl pyrophosphate (FPP) precursor to squalene for use in the sterol biosynthetic 
pathway, resulting in limited production of GGPP. To overcome this, EHY18 was 
constructed by overexpressing the yeast GGPP synthase BTS1 in a yeast system 
containing an overexpressed truncated HMG-CoA reductase (trHMGl) in a upc2-l 
background (Figure 2.1). 
OH V •J- ,n trHMGl OH 
HOOC^ > L .COSCoA - HOOC^ vOH 
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Figure 2.1. Modified sterol biosynthetic pathway in the EHY18 strain. trHMGl and 
BTS1 were overexpressed to accumulate GGPP. 
In gibberellin biosynthesis, two diterpene synthases are utilized in combination 
with a series of P450-dependent oxidases to yield the final gibberellin products.112 In 
Arabidopsis, GGPP is cyclized to e«/-copalyl pyrophosphate by enf-copalyl 
pyrophosphate synthase (GA1),113 and e«/-kaurene synthase (GA2) further cyclizes ent-
copalyl pyrophosphate to ent-kamene (Figure 2.2).114 Two yeast strains were constructed 
to produce the gibberellin precursors. First, the Arabidopsis GA1 gene was expressed in 
EHY18 to accumulate enf-copalyl pyrophosphate, yielding the CPY1 strain 
(EHY18[pCVP2.1]). The CPY2 strain (CPYl[pCVP6.1]) contained both Arabidopsis 
genes GA1 and GA2 to produce e«f-kaurene. 
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Figure 2.2. Gibberellin biosynthetic pathway. GGPP is cyclized to ent-copa\y\ 
pyrophosphate by GA1. Further cyclization is catalyzed by ewf-kaurene synthase (GA2). 
GC-MS analysis of CPY1 crude non-saponifiable lipids (NSL) revealed four main 
peaks with m/z ratios of 290, the mass expected for diterpene alcohols (Figure 2.3). Two 
peaks had mass spectra resembling cyclic diterpene alcohol products (See Appendix D 
for mass spectral data). !H NMR analysis confirmed the presence of e«/-copalol,115 a 
hydrolyzed version of e«?-copalyl pyrophosphate, as the major cyclic product (Figure 
2.4). The second peak was determined through 'H NMR to actually be two cyclic 
products, ewf-manool and e«/-13-epimanool.116 These two compounds co-eluted on GC-
MS and could not be separated. No other cyclic products were detected within a 1% 
detection limit. 
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Figure 2.3. Total ion chromatogram of CPY1 crude NSL. 
ent-Copalol, ewMnanool, and e«7-13-epimanool were most likely derived from 
hydrolysis of enf-copalyl pyrophosphate. Formation of e«7-copalyl pyrophosphate begins 
with protonation of the GGPP terminal olefin and cyclization to form the bicyclic 
carbocation (Figure 2.4). Deprotonation at C-17 yields the exocyclic alkene and the final 
ewf-copalyl pyrophosphate product. Once in an aqueous environment, the pyrophosphate 
moiety readily hydrolyzed to the three products. *H NMR analysis showed e«/-manool 
and e«M3-epimanool in equal amounts (based on peak heights), suggesting non-
enzymatic hydrolysis. The tertiary alcohols were found in much smaller amounts than the 
primary alcohol, suggesting an SN2 mechanism was favored over SN2' or SNI 
mechanisms to the tertiary alcohols. 
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Figure 2.4. Proposed mechanism to e«?-copalol, ewMnanool, and enM3-epimanool. 
Two additional compounds were identified as geranylgeraniol and geranyllinalool 
(Figure 2.5), based on retention times and mass spectra identical to authentic standards 
(Sigma). Geranylgeraniol and geranyllinalool were also detected in the control strain 
EHY18[pRS426Gal], verifying that they are formed from hydrolysis of GGPP (Figure 
2.4). EHY18 was previously reported to accumulate the primary alcohol 
geranylgeraniol,35 and DeJong et al. reported geranyllinalool as a second hydrolysis 
product in their diterpene expression work in yeast, verifying our results. 
OH H,0 
N
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SM2 
OPP 
GGPP 
H2Q 
SN1 or 
SN2' 
OH 
geranyllinalool 
Figure 2.5. GGPP hydrolysis to geranylgeraniol and geranyllinalool. 
The strain co-expressing both GA1 and GA2 was also analyzed, and five major 
diterpene peaks were revealed in the GC-MS analysis of the non-saponifiable lipids 
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(Figure 2.6). Four of these peaks corresponded to the diterpene alcohols found in the 
GA1 strain, identified as geranylgeraniol, geranyllinalool, ewf-copalol, and ent-
manool/ewM3-epimanool. The fifth peak had a mass spectrum resembling that of ent-
kaurene, with an m/z ratio of 272, corresponding to that of a diterpene hydrocarbon. No 
other cyclic products were detected within a 1% detection limit. 
As no reliable lH NMR data were found, Dr. William K. Wilson performed 
quantum mechanical calculations to predict the *H NMR chemical shifts, and the 
observed chemical shifts matched closely. Extensive 2D NMR analysis confirmed the 
structure as ewf-kaurene (See Appendix D for chemical shift assignments). 
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Figure 2.6. Total ion chromatogram of CPY2 crude NSL. 
ercf-Kaurene synthases employ a different cyclization mechanism than ewf-copalyl 
pyrophosphate synthases (Figure 2.7). Whereas e/tf-copalyl pyrophosphate synthesis 
begins with protonation of the terminal double bond in GGPP, en^-kaurene biosynthesis 
starts with formation of a carbocation as a result of loss of the pyrophosphate moiety. The 
third ring forms, followed by deprotonation at C-17 to yield the final tetracyclic product. 
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Figure 2.7. Proposed mechanism for e«7-kaurene cyclization. 
In addition to the gibberellin precursors identified, sterol metabolites were also 
recovered from the cultures. The EHY18 strain contains an intact sterol biosynthetic 
pathway, therefore the sterol precursors squalene and lanosterol, the membrane sterol 
ergosterol, and several lanosterol metabolites were detected in these yeast strains. That 
these were found at such high levels, and that not just ergosterol was isolated, suggested 
that the volume of substrate was too great for complete conversion to ergosterol or 
GGPP. It also indicated that a majority of the FPP was still being funneled into the sterol 
biosynthetic pathway and not towards GGPP. 
Once characterization was complete, the three strains were quantitated by 
growing triplicate cultures to saturation in inducing media. The cultures were harvested, 
and the non-saponifiable lipids (NSL) were quantitated by GC-MS and GC-FID. The 
peak areas of geranylgeraniol, geranyllinalool, e«7-copalol, ercf-manool/e/rt-epimanool, 
and ent-kaurene were compared to that of a known amount of the internal standard 
epicoprostanol (Table 2.1). 
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Table 2.1. GC-FID quantitation data of EHY18[pRS426Gal], CPY1, and CPY2. All 
values are reported in mg/L, with peak areas compared to that of epicoprostanol. 
Strain 
EHY18 
[pRS426Gall 
CPY1 
CPY2 
Geranyl 
linalool 
0.23 ± 0.046 
0.22 ± 0.074 
0.13 ±0.013 
Geranyl 
geraniol 
1.68 ±0.09 
1.03 ±0.17 
0.46 ± 0.05 
ent-
Manool/enf-
Epimanool 
N/A 
0.14 ±0.02 
0.05 ±0.001 
ent-
Copalol 
N/A 
0.53 ±0.04 
0.19 ±0.03 
ent-
Kaurene 
N/A 
N/A 
0.97 ± 0.08 
The CPY1 strain produced approximately 0.53 mg/L of e«7-copalol, along with 
0.14 mg/L of ewf-manool and enf-epimanool. CPY2, on the other hand, produced less of 
these bicyclic diterpene alcohols, with a majority of the ewf-copalyl pyrophosphate being 
cyclized by GA2 to form e«/-kaurene. The e«f-kaurene levels were the highest cyclic 
product yields of the two strains, with nearly 1 mg/L accumulated. No cyclic diterpenes 
were recovered from the media (data not shown). 
The control strain EHY18[pRS426Gal] accumulated 1.9 mg/L of the GGPP 
hydrolysis products geranylgeraniol and geranyllinalool. CPY1 accumulated 
approximately 1.2 mg/L of linear diterpene alcohols, and CPY2 contained the smallest 
amount of geranylgeraniol and geranyllinalool, with only 0.57 mg/L detected. All three 
strains produced more geranylgeraniol than geranyllinalool, suggesting the SN2 
mechanism to the primary alcohol occurred more readily than the SN2' or SNI mechanism 
to the tertiary alcohol. 
GA2 appears to be a more efficient enzyme than GA1, because the co-expressed 
pair accumulates few GA1 products and GGPP hydrolysis products. GA2 was able to 
cyclize a majority of e«?-copalyl pyrophosphate, with only one-third the amount of ent-
copalol, ewMnanool, and e«/-epimanool recovered. CPY2 also accumulated the lowest 
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levels of geranylgeraniol and geranyllinalool, suggesting cyclization occurred faster than 
hydrolysis. This is in sharp contrast to the GA1 strain, in which the GGPP hydrolysis 
products were more abundant than the GA1 cyclization products. 
Overall, the three strains accumulated nearly 2 mg/L of total diterpenes, including 
both linear GGPP hydrolysis products and cyclization products, suggesting the same 
amount of carbon was available for the diterpene pathway in each strain. 
This work demonstrates the utility of S. cerevisiae for diterpene production. A 
yeast strain with five modifications is still viable and producing milligram-scale amounts 
of diterpene compounds. This technology can also be applied to other commercially 
important diterpenes, sesquiterpenes, and triterpenes. The use of modified yeast strains as 
hosts for simultaneous expression of multiple genes, including terpene synthases and P450 
oxidases, can lead to the development of larger libraries of terpenoid products with 
pharmaceutical or commercial potential. 
Furthermore, this work demonstrates the level of competing processes occurring 
in the yeast strains. Geranylgeraniol and geranyllinalool were major diterpene products, 
resulting from hydrolysis of GGPP. These competing pathways divert GGPP away from 
the diterpene synthases, resulting in less cyclized products. If a yeast GGPP phosphatase 
were identified, deleting it could decrease GGPP hydrolysis,74"76 increasing the amount of 
GGPP available for diterpene synthases. 
Another source of competition is from the sterol pathway itself. Squalene, 
lanosterol, and other ergosterol intermediates were found in substantial amounts in the 
extracts, suggesting most of the FPP was utilized for sterol biosynthesis. FPP is converted 
to the sterol precursor squalene by squalene synthase, so deletion of squalene synthase 
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would remove a major competing pathway. Coupled with overexpression of GGPP 
synthase, this modification would likely increase GGPP accumulation, and thus diterpene 
cyclization products, in vivo. Deletion or repression of squalene synthase has greatly 
improved sesquiterpene cyclization product yields, ' ' and it seems likely that this 
manipulation could aid in diterpene production as well. 
Signaling sequences are another limitation affecting diterpene production in vivo. 
| i n 
Plants produce diterpenes within plastids and synthases typically contain signaling 
sequences targeting the proteins to those organelles. These signaling sequences are then 
removed in the plant because they compromise catalysis. The absence of this machinery 
in yeast causes lower yields in vivo. ' The next chapter describes a method that 
increases diterpene synthase expression through inclusion of a chloroplast processing 
enzyme in the yeast strains. 
Experimental Procedures 
Subcloning of GA1 and GA2. The plasmid pGAl-29 containing the Arabidopsis 
GA1 gene in pBluescript was from Tai-ping Sun (Duke University) and Yuji Kamiya 
(RIKEN).113 Marligen ion-exchange columns were used to purify the plasmid DNA, 
following the manufacturer's protocol. The plasmid was digested with Sal I and Not I, 
gel-purified, and ligated into the yeast expression vector pRS426GalR that had been 
digested with the same enzymes. The resulting plasmid was named pCVP2.1. 
The Arabidopsis GA2 plasmid was previously cloned into pRS305biGal by 
former lab member Kelly McCann. The yeast expression vector pRS313biGal and the 
GA2 plasmid DNA were digested with Xba I and BamH I and the fragments were gel-
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purified and ligated, yielding the plasmid pCVP6.1. The pRS313biGal vector contains a 
HIS3 marker that allowed for selection during yeast transformations. 
Construction of yeast strains. EHY18 (MATa. pGALl-BTSl::his pGALl-
trHMGl::LEU2 ura3-52 trpl-A63 leu2-3,112 his3-A200 ade2 Gal+)35 was transformed 
with the pCVP2.1 plasmid using the lithium acetate method,119 with selection on 
synthetic complete medium lacking uracil. This yeast strain was named CPY1 
(EHY18[pCVP2.1]). The CPY1 strain was transformed with the pCVP6.1 plasmid, and 
the resulting transformants were selected on media lacking uracil and histidine. This 
strain, CPYlpCVP6.1], was named CPY2. A control strain was also prepared, in which 
the yeast expression vector pRS426Gal was transformed into EHY18, with selection 
on synthetic complete media lacking uracil. 
Large-scale analysis of GA1 strain. A 1-L culture of CPY1 was grown in 
inducing medium and harvested at saturation. The cell pellet was saponified, extracted, 
and analyzed by GC-MS. The crude NSL was then purified by column chromatography 
using an 80:20 mixture of CEbC^/hexane. Fractions were combined and analyzed by 
GC-MS and 'H NMR. lH NMR analysis confirmed the identities of the e«?-copalol 
structure by comparison with !H NMR literature data (Table 2.2).,15 Additionally, the 
ewMnanool (Table 2.4) and e«/-13-epimanool (Table 2.5) ]H NMR chemical shifts also 
matched those reported in literature.116 
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Table 2.2. Literature values and observed ]H NMR chemical shifts for ewf-copalol. All 
values are reported in ppm. 
Atom # 
14-a 
15a/b 
16 
17-a 
17-b 
18-Me 
19-Me 
20-Me 
Literature value 
5.38, tq, J = 7.0, 1.3 Hz 
4.15, d, J = 6.9 Hz 
1.65 
4.50, brd, J =1.3 Hz 
4.82,appq,J=1.5Hz 
0.86, s 
0.79, s 
0.67, s 
Observed value 
5.392, tq, 7=1.3, 7.0 Hz 
4.155, d,J= 6.9 Hz 
1.66, br s 
4.512, q, 7=1.6, 3.2 Hz 
4.827, q , J= 1.7, 3.3 Hz 
0.870, s 
0.801, s 
0.679, s 
Difference 
0.012 
0.005 
0.01 
0.012 
0.007 
0.01 
0.011 
0.009 
Table 2.3. Literature values and observed ]H NMR chemical shifts for erctananool. All 
values are reported in ppm. 
Atom# 
14 
15-a 
15-b 
16 
17-a 
17-b 
18-Me 
19-Me 
20-Me 
Literature value 
5.90,dd,J= 10.7, 17.4 Hz 
5.03, dd, 7= 1.3, 10.7 Hz 
5.19,dd,J= 1.3, 17.4 Hz 
1.26, s 
4.46,d,J=1.4Hz 
4.80, d, .7=1.4 Hz 
0.85, s 
0.78, s 
0.66, s 
Observed value 
5.910, dd, 7 = 10.8, 17.4 Hz 
5.058, dd,J = 1.3, 10.8 Hz 
5.208, d d , / = 1.3, 17.4 Hz 
1.271, s 
4.475, q , J= 1.6, 3.1 Hz 
4.804, q, J = 1.6, 3.1 Hz 
0.866, s 
0.797, s 
0.671, s 
Difference 
0.01 
0.028 
0.018 
0.011 
0.015 
0.004 
0.016 
0.017 
0.011 
Table 2.4. Literature values and observed !H NMR chemical shifts for e«M3-epimanool. 
All values are reported in ppm. 
Atom# 
14 
15-a 
15-b 
16 
17-a 
17-b 
18-Me 
19-Me 
20-Me 
Literature value 
5.90, dd,J= 10.7, 17.4 Hz 
5.03, dd, 7=1.3, 10.7 Hz 
5.19, dd, J= 1.3, 17.4 Hz 
1.26, s 
4.50, d, 7=1.5 Hz 
4.80, d, J= 1.5 Hz 
0.85, s 
0.78, s 
0.66, s 
Observed value 
5.912, dd,J= 10.8, 17.4 Hz 
5.048, dd,J= 1.3, 10.8 Hz 
5.201,J=1.3, 17.4 Hz 
1.273, s 
4.512, q,7= 1.6, 3.1 Hz 
4.815, q , J= 1.5, 3.1 Hz 
0.866, s 
0.797, s 
0.677, s 
Difference 
0.012 
0.018 
0.011 
0.013 
0.012 
0.015 
0.016 
0.017 
0.017 
Large-scale analysis of GA2 strain. A 1-L culture of CPY2 was grown to 
saturation in galactose and harvested by centrifugation. The cell pellet was saponified and 
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extracted, and the crude NSL was analyzed by GC-MS. The NSL was then purified by 
column chromatography (6 g silica gel 60) with a gradient of hexane/ether, starting with 
100% hexane. The pure hexane fractions were further analyzed by *H and 13C NMR, and 
COSY, DEPT, and HMBC 2D NMR experiments were also undertaken. All spectra were 
collected using a Bruker 500 MHz spectrometer. Chemical shifts were compared to 
values predicted by quantum mechanical calculations (Table 2.5) and C literature values 
(Table 2.6 and Appendix C).121 
Table 2.5. Predicted values and observed !H NMR chemical shifts for e«?-kaurene. 
Asterisks (*) or daggers (f) indicate chemical shifts could be interchanged. All values are 
reported in ppm. 
Atom# 
1-a 
1-b 
2-a 
2-b 
3-a 
3-b 
5 
6-a 
6-b 
7-a 
7-b 
9 
11-a 
11-b 
12-a 
12-b 
13 
14-a 
14-b 
15-a 
15-b 
17-a 
17-b 
18-Me 
19-Me 
20-Me 
Predicted 
value 
0.73 
0.82 
2.63 
4.69 
4.78 
0.83 
0.81 
1.01 
Observed value 
0.738, tdd, J= 13, 4.0, 0.9 Hz 
1.806, dtd,J= 12.8, 3.5, 1.6 Hz 
1.393, m 
1.610, m 
1.122, td, .7=13.6,4.6 Hz 
1.373, m 
0.787, dd, J = 12.0, 2.0 Hz 
1.547, m 
1.323, m 
1.516, m 
1.493, m 
1.058, m 
1.586, m 
1.586, m 
1.647, m 
1.471, m 
2.631 brt, J= 5.6 Hz 
1.994, dd ,J= 11.4, 2.5 Hz 
1.094, dddd, J= 11.4, 2.4,2.4, 2.0 Hz 
2.064T, ddd, J= 3.0, 2.3, 0.9 Hz 
2.042f, ddd, J= 3.0, 2.3, 1.0 Hz 
4.729* 
4.789* 
0.853, s 
0.810, s 
1.020, s 
Difference 
0.008 
-0.033 
0.001 
0.039 
0.009 
0.023 
0 
0.010 
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Table 2.6. Comparison of literature and observed C NMR chemical shifts for ent-
kaurene. All values are reported in ppm. 
Atom# 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
Literature 
value 
41.3 
18.7 
42.0 
33.3 
56.1 
20.3 
40.4 
44.2 
56.1 
39.3 
18.1 
33.3 
44.2 
39.9 
49.2 
156.0 
102.8 
33.7 
21.7 
17.6 
Observed 
value 
40.43 
18.66 
42.08 
33.27 
56.27 
20.25 
41.24 
44.23 
56.07 
39.33 
18.15 
33.31 
44.05 
39.84 
49.22 
156.20 
102.79 
33.66 
21.64 
17.59 
Difference 
-0.87 
-0.04 
0.08 
-0.03 
0.17 
-0.05 
0.84 
0.03 
-0.03 
0.03 
0.05 
0.01 
-0.15 
-0.06 
0.02 
0.2 
-0.01 
-0.04 
-0.06 
-0.01 
Quantitation of yeast strains. Triplicate 100-mL galactose cultures were grown 
to saturation and harvested by centrifugation at 3000 rpm for 10 min. The cell pellets 
were saponified in 10% KOH in 80% EtOH. To this were added the antioxidant BHT (2 
mg/g cell pellet) and 100 ug of epicoprostanol as internal standard prior to 2 h incubation 
at 70 °C. Once the mixtures were cooled to room temperature, 5 mL distilled water was 
added, and the mixtures were extracted with 3 x 15 mL hexanes. The solvent was 
removed in vacuo, and the residues were transferred to GC vials with CH2CI2 and 
analyzed by GC-MS and GC-FID. 
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Chapter 3 
The production of mature plastid proteins in yeast: co-expressing a 
chloroplast processing enzyme facilitates metabolic engineering and 
enzyme investigation in diterpenes 
Introduction 
Biosynthesis of diterpenes in plants occurs in plastids,122"124 and therefore 
diterpene synthases usually contain N-terminal transit peptide signal sequences directing 
them to the plastids.90 Once in the organelle, the transit sequences are cleaved to form the 
mature, functional diterpene synthases. The initial full-length protein containing the 
transit peptide sequence expressed in E. coli has poor enzymatic activity, whereas 
removal of the signal sequence has been demonstrated to increase enzymatic activity and 
- 1 • , • 92-94 
aid m enzyme characterization. 
Pseudomature proteins are heterologously expressed proteins lacking the transit 
peptide. These enzymes are generated by making a subclone without the signal sequence, 
but with an artificial start site introduced at the beginning of expected mature protein. 
Pseudomature proteins differ from conventional mature proteins because they retain this 
adventitious methionine, and pseudomature diterpene synthases often have better activity 
ST Q*^  OS 
than their full-length counterparts when expressed in E. coli. ' ' However, the exact 
location of the cleavage site is not readily predictable, therefore extensive empirical 
experiments are often necessary to determine the best site for N-terminal 
truncation.93'95'96'125 Moreover, one cannot be certain that the introduced methionine in 
the pseudomature protein does not alter catalysis in some way. However, plants encode 
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proteins known as chloroplast processing enzymes (CPE), which cleave transit peptides 
once proteins enter the plastid.91 Described herein are experiments establishing that co-
expression of a chloroplast processing enzyme with a diterpene synthase promotes 
truncation of the signaling sequence within the heterologous host, removing the necessity 
for manual truncation through PCR amplification. This approach generates the mature 
diterpene synthase, increasing diterpene synthase biosynthetic activity in our yeast 
system. 
Results and Discussion 
The Arabidopsis chloroplast processing enzyme (CPE, At5g42390) was PCR-
amplified from a cDNA and co-expressed in EHY1835'111 containing either the Abies 
grandis (grand fir) abietadiene synthase (AgAS) or the Arabidopsis e«/-copalyl 
pyrophosphate synthase (,4fGAl)113 and e«/-kaurene synthase {AtGA2)UA genes (Table 
3.1). Control strains expressing only diterpene synthases were grown in parallel, and the 
diterpene products accumulating in the cell pellets and media were analyzed. Triplicate 
cultures were grown and harvested to provide more accurate data. 
Table 3.1. Summary of yeast strains with and without CPE. All yeast strains contain 
MATa pGALl-BTSl::hisG pGALl-trHMGl::LEU2 ura3-52 trpl-A63 leu2-3,112 his3-
A200ade2 Gal+. 
Yeast strain 
EHY18[pEH9.01 
EHY18rpEH9.0irpAMB5.31 
EHY18[pCVP26.11 
EHY18fpCVP26.lirpAMB5.31 
Characteristics 
AgAS::URA3 
AzAS::URA3 AtCPE::HIS3 
AtGAl+AtGA2::URA3 
AtGAl+AtGA2::URA3 AtCPE::HIS3 
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The cell pellets from EHY18[pEH9.0] and EHY18[pEH9.0][pAMB5.3] were 
saponified, and the non-saponifiable lipids (NSL) contained the majority of the diterpene 
products (Table 3.2). The NSL were thus used for quantitation, as insignificant levels of 
diterpene products were isolated from the media (<1% of the total). GC-MS analysis of 
the NSL showed that the cultures produced abietadiene as the major diterpene product. 
Abietadiene synthase was previously reported to catalyze cyclization of geranylgeranyl 
pyrophosphate (GGPP) to the intermediate (+)-copalyl pyrophosphate, which is then 
cyclized further to (-)-abieta-7(8),13(14)-diene (Figure 3.1). 126 
0- OPP -err copalyl pyrophosphate GGPP ' " ' x abieta-7(8),13(14)-diene 
Figure 3.1. Cyclization of GGPP to abietadiene by abietadiene synthase. 
Table 3.2. GC-FID quantitation of EHY18[pEH9.0] NSL with and without CPE co-
expression. Peak areas were compared to that of the internal standard epicoprostanol. 
Strain 
EHY18[pEH9.0] 
EHY18rpEH9.01[pAMB5.3] 
Abietadiene 
(mg/L) 
5.91 ±0.55 
9.11 ±0.58 
Geranylgeraniol 
(mg/L) 
N.D. 
N.D. 
Squalene 
(mg/L) 
14.18=1=2.16 
8.29 ±1.02 
The amount of abietadiene isolated from the CPE-expressing strain increased 1.5 
times in comparison to the strain without the CPE. Both strains accumulated a significant 
amount of abietadiene, with nearly 6 mg/L in the strain without the CPE and over 9 mg/L 
in the strain with the CPE. Unlike the diterpene systems described in Chapter 2, both the 
control strain and the strain co-expressing the CPE produced abietadiene but did not 
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accumulate substantial levels of the GGPP hydrolysis products geranylgeraniol or 
geranyllinalool. 
Because the yeast strains have intact sterol biosynthetic pathways, squalene was 
also isolated but at much higher levels than the diterpene products. In the strain without 
the CPE, approximately 14 mg/L of squalene was accumulated, suggesting that the 
amount of carbon flux was too great for the enzymes in the sterol pathway to process it 
efficiently. The strain with the co-expressed CPE, however, demonstrated a large 
decrease in squalene accumulation, with only 8.3 mg/L recovered. This further supports 
the observation that CPE co-expression increases abietadiene synthase activity in the 
yeast. 
Usually, most FPP funnels through the sterol biosynthetic pathway instead of 
being used for GGPP production. Overexpression of GGPP synthase shunted more FPP 
to GGPP biosynthesis and therefore provided more substrate for diterpene synthesis, 
decreasing the amount of carbon routed towards sterol biosynthesis.35 
More dramatic changes were observed in the strains co-expressing GA1 and GA2 
with the CPE (Table 3.3). As seen in the strains containing abietadiene synthase, almost 
all of the e«/-kaurene was isolated from the cell pellets, with less than 1% of the ent-
kaurene found in the media. From these results, the amount of e«7-kaurene accumulating 
in the CPE co-expression strain was 10 times higher than that observed in the strain 
without the CPE. The parent strain accumulated approximately 0.25 mg/L e«/-kaurene, 
while the strain with the CPE accumulated approximately 2.5 mg/L. This is the most ent-
kaurene observed in any strain to date. 
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Table 3.3. GC-FID quantitation of EHY18[pCVP26.1] NSL with and without CPE co-
expression. Peak areas were compared to that of the internal standard epicoprostanol. 
Strain 
EHY18[pCVP26.11 
EHY18rpCVP26.1irpAMB5.31 
ewf-Kaurene 
(mg/L) 
0.25 ± 0.08 
2.47 ±1.34 
Geranylgeraniol 
(mg/L) 
3.54 ±1.26 
2.46 ± 0.63 
Squalene 
(mg/L) 
8.18 ±1.85 
6.00 ± 0.73 
The CPE co-expression greatly improved GA1 and GA2 activity, as shown by the 
substantial difference in enf-kaurene accumulation. No significant amounts of the ent-
kaurene intermediates e«/-copalol or ewf-manool/eHf-13-epimanool were observed (<1% 
of ent-kaurene), suggesting that GA2 enzymatic activity greatly increased and more 
efficiently cyclized ewf-copalyl pyrophosphate to ent-kmrene. 
In addition to ent-kaurene, a considerable amount of geranylgeraniol was also 
isolated, with approximately 3.0 mg/L accumulating in both EHY18[pCVP26.1] and the 
CPE-expressing strain. The large amount of geranylgeraniol isolated suggests that the 
GA1 and GA2 enzymes were not as efficient as the abietadiene synthase. As observed in 
the abietadiene strains, the amount of squalene accumulation was substantial, with over 8 
mg/L of squalene isolated from EHY18[pCVP26.1]. The amount of squalene decreased 
significantly to 6 mg/L when the CPE was expressed. e«?-Kaurene production increased 
at the same rate that squalene accumulation decreased, again consistent with CPE 
increasing GA1 and GA2 activity. 
Co-expressing Arabidopsis CPE improved abietadiene production somewhat less 
than it did in the enf-kaurene-producing strains, consistent with better cleavage when 
CPE and cyclase both come from Arabidopsis than when they are from different 
organisms. This difference may reflect the evolutionary distance between A. grandis and 
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Arabidopsis. The CPE substrate recognition sites may not be similar enough to efficiently 
cleave the transit peptide from the other organism. 
This work is the first example of improving the function of a plastid enzyme by 
co-expression with CPE. Some previous efforts generated pseudomature proteins by 
initiating transcription with a false start site after the signal sequence. However, this 
method has severe limitations. Transit peptides vary in length, from short sequences to up 
to 140 amino acids cleaved in some cases,91 and variation in sequences make it difficult 
to predict the exact cleavage site. ' Transit peptides lack defined sites that clearly 
indicate the precise location of the cleavage site.128 The best existing methods to locate 
signal sequence boundaries rely on broad trends. The sequences are typically comprised 
of 20-35% serine and threonine as well as numerous small hydrophobic residues such as 
alanine, valine, or glycine. While large amounts of basic amino acids, such as lysine or 
arginine, are not found, the peptides normally have an overall positive charge, with 
almost no acidic amino acid residues.129 
The A. grandis abietadiene synthase and Arabidopsis GA1 and GA2 protein 
sequences, together with sequences from other characterized diterpene synthases, were 
downloaded from the National Center for Biotechnology Information (NCBI) website 
and analyzed for these general traits (Figure 3.2). All of these enzymes have putative 
transit peptides containing the proposed characteristics. Their N-terminal regions 
contained high levels of serine, threonine, and small hydrophobic molecules, and few 
acidic residues were observed. Somewhere between 75 and 140 residues, the density of 
acidic residues increased 5- to 10-fold, indicating the boundary to the mature protein had 
been crossed. However, no specific motifs marked the location of the native site. ' ' 
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None of the peptides have obvious amino acid motifs in the putative transit peptide 
region, demonstrating the difficulty in determining the exact truncation site required. 
10 20 30 10 50 
AgAS LflDgL T S 
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SrGA2 - -BD||T 
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SrGAI fld D f l - IjgegJG 
SrGA2 R 3 - S P N 5 P K 
Figure 3.2. Protein alignment of the N-termini of seven diterpene synthases. AgAS is A. 
grandis abietadiene synthase, TbTS is Taxus brevifolia taxadiene synthase, PtDS is a 
Pinus taeda putative diterpene synthase, AtGAl is Arabidopsis GA1, AtGA2 is 
Arabidopsis GA2, SrGAI is Stevia rebaudiana copalyl pyrophosphate synthase, and 
SrGA2 is S. rebaudiana e«/-kaurene synthase. Triangles denote the putative cleavage 
sites for AgAS, TbTS,93 AtGAl, and AtGA2 . Areas of consensus sequences are shaded. 
The signaling sequence in abietadiene synthase was initially suggested to 
126 
comprise amino acids Metl-AlallO. However, a series of truncations were 
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constructed, and truncation after Trp93 dramatically decreased enzymatic activity.95 The 
conserved DDXXD motif necessary for catalysis had been removed; the transit peptide 
was shorter than initially predicted. Peters et al. found the highest activity when the first 
84 amino acids were cleaved.95 Analysis of the first 84 amino acids of the NCBI 
abietadiene synthase sequence showed 29% serine and threonine, as well as 21% small 
hydrophobic residues. Only three acidic residues were found, consistent with the current 
best understanding of signal sequence characteristics. 
More importantly, the CPE-cleaved abietadiene synthase working in vivo has a 
dramatically different product profile than the pseudomature proteins that have been 
developed to date. The native enzyme isolated from A. grandis was originally reported to 
generate abietadiene with high accuracy (over 90% abietadiene).92'126 However, the 
pseudomature abietadiene synthases generate a diverse set of products in which 
abietadiene is a minor component.95 In contrast, our metabolically engineered systems 
produce abietadiene at >95% of the product profile. Whether these differences are due to 
cleavage at a different site or the presence of the adventitious methionine remains to be 
determined. 
Pseudomature derivatives of Arabidopsis GA1 showed similar trends to those 
seen in abietadiene synthase. The transit peptide in Arabidopsis GA1 was initially 
reported as approximately 50 amino acids.113 However, Prisic and Peters later generated a 
series of pseudomature proteins at several sites along the GA1 protein and demonstrated 
that a 50-amino acid truncation yielded a very unstable protein.96 Instead they reported an 
84-amino acid cleavage that had better enzymatic activity than the immature enzyme. 
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This cleavage site was also at an exon boundary, which the authors argue makes this 
position a plausible location.96 
However, the 84-amino acid sequence is more acidic, with 8% acidic residues and 
7% basic residues. The region contained 26% serine and threonine, but these were 
present only in the first 60 amino acids. If this cleavage site is indeed correct, the 
guidelines for predicting signal sequences need revision. Without making every possible 
pseudomature protein along this region, the possibility exists that a shorter peptide could 
be deleted and retain good activity. A further possibility is that the adventitious 
methionine that initiates translation compromises enzymatic activity in the derivative 
from which 50 residues was deleted. 
The transit peptide in Arabidopsis GA2 was also tentatively identified as 44 
amino acids.114 This region of GA2 had 25% serine or threonine and 18% basic residues. 
Notably, the sequence also contained a higher level of acidic residues, with 11% 
observed. No pseudomature proteins have been described for GA2 to date. 
Because plastid proteins contain transit peptides, each plant must encode a CPE or 
a similar protein that cleaves the transit peptides within the plant. Chloroplast processing 
enzymes have been identified in many plants, including Pisum sativa and Arabidopsis 
thaliana.91 These enzymes are metalloendopeptidases, which typically have rather broad 
substrate specificities. CPE was previously reported to process proteins targeted to many 
different locations within the chloroplast and to cleave proteins that serve roles in varied 
biosynthetic pathways.91 Typically, the transit peptide is cleaved in a single proteolytic 
step, resulting in a mature protein, and the cleaved transit peptide is further degraded 
within the organelle.130 
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As a plastid protein itself, CPE is translated as a preprotein with a transit peptide 
that is cleaved once entering the plastid.91 Analysis of the CPE protein sequence 
uncovered a putative transit peptide rich in serine and threonine residues and small 
hydrophobic amino acids, consistent with reported characteristics. The CPE preprotein 
has little activity in E. coli,91 and its activity in yeast shows that the CPE apparently 
cleaves its own sequence as well to yield the mature protein, as no other chloroplast 
enzymes are present in our yeast strains. This is supported by Richter and Lamppa, who 
reported that the P. sativa CPE was capable of processing its own transit peptide in E. 
coli91 
The differences in product improvement between the abietadiene synthase from a 
gymnosperm and e«?-kaurene synthase from Arabidopsis suggest that the Arabidopsis 
CPE may not be optimal for enzymes from other organisms. Subtle differences in the 
recognition sequences may be more efficiently cleaved by a CPE from the same organism 
or a close relative. The possibility that different CPEs may cleave different sites cannot 
be precluded. As more genomic sequence becomes available it will be straightforward to 
develop an array of yeast strains expressing CPEs from the major plant groups to 
optimize cleavage. However, we demonstrate that even without an organism-specific 
CPE, the Arabidopsis CPE improves diterpene yields significantly. 
In addition to increasing diterpene production, this approach can be utilized for 
expression of any plastidial protein. For example, many monoterpenes are also produced 
in the plastids and a large number of monoterpene synthases encode a transit peptide. Co-
expression of a chloroplast processing enzyme with a monoterpene synthase could 
potentially result in increase of monoterpene yields in vivo. 
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This work demonstrates a novel and facile approach to increasing diterpene 
production in yeast. Co-expression of a chloroplast processing enzyme removes the need 
for manual truncation of the diterpene synthase transit peptide and in many cases should 
provide a more active enzyme than pseudomature proteins. Previously, multiple 
truncations had to be examined to find the best protein in terms of solubility, purification, 
and enzymatic activity, but this approach allows in vivo cleavage to yield the mature 
protein. This method shows vast improvements compared to previously reported yields 
and demonstrates the great potential for this strategy. 
Experimental Procedures 
RT-PCR to obtain a cDNA. mRNA from 7-day Arabidopsis seedlings 
(Columbia) was a generous gift from Prof. Rebekah Rampey, a former graduate student 
from Prof. Bonnie Bartel's laboratory. Reverse-transcription PCR was performed 
following the manufacturer's protocol to obtain a cDNA (Ambion, Austin, TX). 
PCR amplification of CPE from cDNA. The full-length Arabidopsis CPE gene 
sequence (At5g42390) was obtained from NCBI and used to develop primers for PCR 
amplification from the cDNA library. Because of the length of the CPE gene (3.8 kB), it 
was necessary to amplify the gene in two parts: from Sal I to EcoR I, and from EcoR I to 
Not I. For the first fragment, the PCR mixture was as follows: 1 uL 7-day seedling 
cDNA, 1 uL of the forward primer pCVP18-Fl 5'-
TAGTCGACAATTATGGCTTCATCG-3' (Sal I restriction site underlined), 1 uL of the 
reverse primer pCVP18-R2 5 '-ACCGGAATTCCATGGCAATG-3' (EcoR I restriction 
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site underlined), 4 uL dNTPs, 5 uL High-Fidelity buffer, 0.2 u.L Triple Master 
polymerase, and 38 uL mqH20. The back fragment contained the same mixture, except 
the primers used were pCVP18-F7 5'-CATTGCCATGGAATTCCGGTTTACT-3' (EcoR 
I restriction site underlined) and pCVP18-Rl 5'-
GCGGCCGCTCAGGTTGTTGGTCTTGT-3'(M?f I restriction site underlined). 
Construction of the full-length CPE-containing plasmid. The two CPE 
fragments, Sal I to EcoR I, and EcoR I to Not I, were ligated into TOPO-TA vector, and 
clones containing the inserts were sequenced. Large-scale cultures of clones with the 
correct sequences were grown and DNA isolated, yielding two plasmids pAMB3.0 and 
pAMB4.0, corresponding to the front and back pieces of the CPE, respectively. 
The two plasmids pAMB3.0 and pAMB4.0 were digested with their 
corresponding restriction enzymes and ligated into pRS313Gal that had been digested 
with Sal I and Not I. The three-piece ligation was then transformed into E. coli and plated 
on LB + Amp. Clones were screened for the presence of the insert, and the correct clone 
was sequenced to ensure the full-length gene was obtained with the correct sequence. The 
final plasmid was named pAMB5.3. 
Subcloning GA1 and GA2 into one plasmid. A plasmid containing both Arabidopsis 
GA1 and GA2 was constructed. First, GA2 and a bi-directional galactose (BiGal) 
promoter were subcloned into pRS426 with BamH I and Not I to give the plasmid 
pCVP6.3. GA1 was PCR-amplified to insert new restriction sites using the primers 
GA1F4 5'- TACCGCGGAATTATGTCTCTTCAGTATCATG-3' and GAlNotIR 5'-
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GCGGCCGCCTAGACTTTTTGAAACAAG -3 ' . The gel-purified PCR product was 
cloned into pCVP6.3 with Sac II and Not I, resulting in the final plasmid pCVP26.1. 
Construction of yeast strains. Two control strains were first constructed. EHY18 
was transformed with either the pCVP26.1 plasmid or pEH9.0, the Abies grandis 
abietadiene synthase in pRS426Gal (constructed by former lab member Dr. Elizabeth 
Hart). These two yeast strains, EHY18[pCVP26.1] and EHY18[pEH9.0], were selected 
on synthetic complete media lacking uracil and transformed with the pAMB5.3 plasmid. 
The final transformants were screened by growing on synthetic complete media lacking 
both uracil and histidine. 
Identification and quantitation of products generated in yeast strains. All 
strains were grown to saturation in inducing medium and harvested by centrifugation. 
The cell pellets were saponified and extracted with 3><15 mL hexanes, with 100 uL of 
the internal standard epicoprostanol (2.5 mg in 1 mL ethanol) added prior to 
saponification. The NSL were partitioned between one-half volume water and 3 x 1 5 mL 
hexanes, and solvent was evaporated in vacuo and residues transferred to GC vials with 
CH2C12. Samples were analyzed on GC-FID and GC-MS. 
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Chapter 4 
Manipulation of media pH to increase nerolidol or farnesol production 
Introduction 
Metabolic engineering has recently emerged as an alternative to obtaining 
terpenoids from natural sources and synthesis. Saccharomyces cerevisiae ia a particularly 
attractive host for heterologous expression of sesquiterpene biosynthetic genes because 
fungi biosynthesize the sesquiterpenoid precursor farnesyl pyrophosphate (FPP) as an 
intermediate in sterol biosynthesis (Figure 4.1). Several yeast strains have been 
developed to increase FPP accumulation, focusing on increasing the amount of substrate 
available through a combination of deleting or repressing competing pathways and 
increasing carbon flux through the pathway. For example, a solubilized form of the rate-
limiting enzyme HMG-CoA reductase (trHMGl) has been overexpressed to increase the 
amount of carbon available for the pathway, and the competing enzyme squalene 
synthase (ERG9) has been repressed or deleted in an effort to increase FPP accumulation 
further.82"85'117'131 However, FPP appears to hydrolyze readily when it accumulates in 
yeast. Strains with deleted or repressed ERG9 produce farnesol41'132 (Figure 4.2) as a 
dominant product of FPP hydrolysis, and when sesquiterpene synthases (the enzymes 
cyclizing FPP to hydrocarbon products) are expressed in these strains, farnesol 
predominates over cyclized products. 
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OPP ERG9 
FPP squalene ergosterol 
Figure 4.1. S. cerevisiae sterol biosynthetic pathway. ERG9 (squalene synthase) and 
trHMGI (HMG-CoA reductase) are noted. 
Results and Discussion 
We constructed the yeast strain PMY1, an erg9 mutant that overexpresses 
trHMGI.82 The trHMGI overexpression promotes FPP biosynthesis, which cannot be 
converted to squalene because of the erg9 deletion, and we found that PMY1 
accumulates two major FPP hydrolysis products, the primary alcohol farnesol and the 
tertiary alcohol nerolidol (Figure 4.2). 
OPP 
H20 
FPP Farnesol Nerolidol 
Figure 4.2. Hydrolysis of FPP forms the primary alcohol farnesol or the tertiary alcohol 
nerolidol. 
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S. cerevisiae encodes two phosphatases, DPP174 and LPP1,75 which hydrolyze 
FPP and other prenyl pyrophosphates.76 We speculated that one phosphatase might 
generate farnesol through an SN2 mechanism, while the other could form nerolidol by 
SN2' or SNI displacements. We investigated the impact of these phosphatases on the 
metabolically engineered profile through mutagenesis experiments. Each phosphatase 
was deleted by replacing the gene with a geneticin-resistant marker, KanMX, to give 
PMY2 {dppl A) and BEJY14 (JpplA). These were expected to substantially reduce the 
amounts of FPP hydrolysis products produced in these yeast strains, as DPP1 was 
previously implicated in decreasing farnesol production in engineered yeast. The 
sesquiterpene content of media and cell pellets were assayed. FPP hydrolysis products 
were found not in the cell pellet, but were isolated in the media (Table 4.1). 
Table 4.1. PMY1, PMY2, and BEJY14 media extracts were quantitated by GC-FID. 
Farnesol and nerolidol values are reported in mg/L. All strains were grown in YPGHE 
and possess MATa. erg9::HIS3 heml::TRPl ura3-52 trpl-A63 his3-A200 ade2 GAL+. 
Strain 
PMY1 
PMY2 
BEJY14 
Genotype 
trHMGl::LEU2 
dppl A::KanMX trHMGl::LEU2 
lpplA::KarMX trHMGl::LEU2 
Farnesol 
(mg/L) 
28.6 ± 1.35 
16.7 ±1.23 
28.3 ± 3.09 
Nerolidol 
(mg/L) 
3.10 ±0.061 
0.943 ± 0.0772 
1.18 ±0.201 
Although the phosphatase deletions had statistically significant effects on farnesol 
and nerolidol production, these changes were not dramatic enough to suggest that LPP1 
and DPP1 are the primary modes of FPP hydrolysis. The total amounts of C15H26O 
compounds were not impacted by the IpplA deletion, but the dppl A strain accumulated 
somewhat less of these compounds. Farnesol production was not significantly impacted 
by deleting LPP1 but was significantly reduced in the dppl A strain. This led to the 
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conclusion that DPP1 played a role in famesol production, but whether it directly 
mediated FPP hydrolysis to farnesol in vivo or altered sterol precursor biosynthesis and 
metabolism indirectly remains to be determined. One striking observation was that the 
major product did not vary between the three strains; farnesol production was still the 
major outcome. The farnesol to nerolidol ratio of PMY1 (9.22) was somewhat lower than 
that of PMY2 (17.7) and BEJY14 (24.0). Nerolidol production was decreased by deleting 
either LPP1 or DPP1. The consistency in nerolidol data between PMY2 and BEJY14, 
however, suggested this SN2' or SNI displacement to the tertiary ally lie alcohol occurred, 
in part, outside of the environment of LPP1 or DPP1. 
Because no other phosphatase seemed an obvious candidate for the enzyme that 
hydrolyzes FPP to nerolidol, the possibility that these compounds are nonenzymatic 
products was investigated. The stereochemistry of nerolidol isolated and purified from 
PMYl[pRS316Gal] was established with 'H NMR analysis using a lanthanide chiral shift 
reagent. Chiral shift reagent NMR analysis133 has been well established and is often more 
reliable than polarimetry.134 Whereas polarimetry is susceptible to changes in solvent, 
concentration, and trace impurities, chiral shift reagent NMR is a non-optical method to 
distinguish enantiomers based on differences in chemical shifts after addition of a chiral 
shift reagent. Additionally, very little material is needed for NMR analysis, and the use of 
a high-field magnet enables fine analysis with high precision. Comparison of peak areas 
or peak heights can then determine enantiomeric ratios. Linalool is a monoterpene 
homolog of nerolidol, and the lanthanide shift reagent Eu(hfc)3 (europium tris[2-
(heptafluropropylhydroxymethylene)-(+)-camphorate]) was reported to resolve the *H 
NMR spectra of (fl)-linalool and 0S)-linalool.134 
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We first studied the linalool model system by analyzing a racemic standard 
(Fluka) by *H NMR and slowly adding Eu(hfc)3 (Sigma) to the samples (data not shown). 
After addition, the two enantiomers began to exhibit differing *H NMR spectra, with the 
olefinic peaks shifting downfield. Further addition of the shift reagent also split the 
doublet into a doublet of doublets, showing the mixture was in fact racemic. Addition of 
a small amount of an (i?)-linalool standard (Fluka) slightly increased the peak height of 
the doublet corresponding to that enantiomer. A racemic nerolidol standard (Sigma) was 
also tested using the same system, with similar results - the two enantiomers were 
evident, and the olefinic peaks began to split into a doublet of doublets with equal peak 
heights, signifying a racemic mixture. 
The same procedure was then undertaken for the nerolidol purified from 
PMYl[pRS316Gal]. Addition of Eu(hfc)3 shifted the allylic peak (5.232 ppm) further 
downfield, and eventually the doublet split into a doublet of doublets (J= 17 Hz and 3.6 
Hz, Figure 4.3), suggesting that both enantiomers were present. Furthermore, the peak 
areas were equal, leading to the conclusion that nerolidol was present as a racemic 
mixture. Because most sesquiterpene synthases that catalyze formation of nerolidol 
produce a single enantiomer,135"137 this result supported the possibility of nonenzymatic 
FPP hydrolysis. 
52 
dd, J=3.6, 4.4 Hz Spectrum C expanded 20 times 
T — ' — ' — ' — ' — I — ' — ' — ' — ' — I — ' — ' — ' — ' — I — ' — ' — ' — ' — I — ' — ' — ' — ' — I — ' — ' — ' — ' — I — ' — ' — ' — ' — I — ' — ' — ' — ' — I — ' — ' — r — * - 1 — ' — ' — — 
5.50 5.45 5.40 5.35 5.30 5.25 5.20 5.15 5.10 5.05 ppm 
Figure 4.3. !H NMR spectra of nerolidol purified from PMYl[pRS316Gal] before and 
after addition of Eu(hfc)3. Spectrum A is nerolidol prior to addition of the shift reagent 
and spectrum B shows the 5.232 doublet shifting downfield after addition of Eu(hfc)3 and 
the doublet starts splitting into a triplet. Spectrum C shows a further downfield shift and 
the peaks splitting into a doublet of doublets. Spectrum D shows spectrum C after 
resolution enhancement, with fine splitting into a doublet of doublets (J =17 Hz, 3.6 Hz). 
As farnesol and nerolidol were isolated from the culture media, the media 
components were assessed for their possible influence on the sesquiterpene product 
profile in PMY1 with and without empty vector. Rich (YP) and synthetic (SC-U) media 
were examined, and yeast grown in SC-U media gave dramatically different results than 
previously seen (Figure 4.4). The synthetic media produced nerolidol as the major 
product and farnesol was less than half the level of nerolidol. Two formal possibilities 
could account for the difference in results between media: either some component present 
in YP promotes farnesol production, or some component in synthetic medium facilitates 
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nerolidol formation. To distinguish between these possibilities, a 1:1 mixture of YP and 
SC-U media was tested. The product profile resembled that of pure YP, with farnesol 
produced at levels seven times higher than nerolidol. The individual components of YP 
were also tested, to determine if one component could be directing farnesol production. 
Cultures grown in SC-U supplemented with either peptone or yeast extract also produced 
farnesol as the major product (Table 4.2). 
32.00 
SC/YP 
Figure 4.4. GC-FID quantitation results from PMY1 and PMYl[pRS316Gal] grown in 
YP, SC-U, or a 1:1 mixture of YP and SC-U. Farnesol is denoted by patterned columns 
while nerolidol is represented by white columns. 
The possibility that pH changes could impact hydrolysis was considered early in 
this investigation, but both media had pH values too close to neutral (pH 5.5-7) to 
promote pyrophosphate elimination. An experiment was conducted to establish the extent 
to which yeast cultures become more acidic during growth. Cultures of PMY1 or 
PMYl[pRS316Gal] (50 mL) were grown in the three media conditions and the pH was 
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measured at initial inoculation, log-phase, and saturation phase (Table 4.2). Controls with 
no yeast inoculation were incubated in parallel. 
Table 4.2. Cultures became more acidic 30 h and 48 h after inoculation. 
Strain 
PMY1 
PMYl[pRS316Gal] 
PMYl[pRS316Gall 
PMYl[pRS316Gal] 
PMYl[pRS316Gal] 
None 
None 
None 
None 
None 
Media 
YP 
SC-U 
SC-U/YP 
SC-U + yeast 
extract 
SC-U + 
peptone 
YP 
SC-U 
SC-U/YP 
SC-U + yeast 
extract 
SC-U + 
peptone 
Initial 
pH 
6.5-7 
5.5 
6 
6 
6-6.5 
7 
5.5 
6 
6-6.5 
6-6.5 
After 
30 h 
6 
5-5.5 
5.5-6 
5.8-6.1 
6-6.5 
6.5-7 
5.5 
6-6.5 
6-6.5 
6.5 
After 
48 h 
5.5 
4-4.5 
5 
Not 
measured 
Not 
measured 
6.5-7 
5.5 
6-6.5 
Not 
measured 
Not 
measured 
Major 
product 
Farnesol 
Nerolidol 
Farnesol 
Farnesol 
Farnesol 
N/A 
N/A 
N/A 
N/A 
N/A 
The SC-U culture started at a more acidic pH than the YP medium or mixtures of 
YP and SC-U, but all three media became more acidic as the yeast grew. The more 
neutral pH of the YP media appeared to direct FPP hydrolysis toward production of 
farnesol, while the more acidic SC-U increased formation of nerolidol (Table 4.3). 
Nerolidol formation becomes dominant when the final pH is below 5, so cultures that 
start with pH 6.5-7 have sufficient buffering capacity to remain above this level, 
accumlating farnesol as the major product. Most of the product accumulates once the 
medium has acidified, and so the final pH is probably more influential in directing the 
direction of FPP hydrolysis. 
To preclude the possibility that an unidentified individual component of the media 
caused the difference in FPP hydrolysis product ratios, YP media was acidified to mimic 
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the pH of SC-U, and NaOH was added to SC-U media to mirror YP pH. The basified SC-
U media led to results similar to that of YP; farnesol was isolated as the major product 
(Table 4.3). Acidic YP began resembling SC-U results as well, with a 1:1 mixture of 
farnesol and nerolidol produced when the pH was lowered to 5-5.5. These results 
confirmed that media pH was the controlling factor. 
Table 4.3. pH-altered cultures produced different amounts of farnesol and nerolidol than 
the original cultures. All cultures were grown with galactose, ergosterol, and hemin. pH 
was measured at inoculation and after 48 h incubation. 
Media 
YP + MOPS 
YP + acetic 
acid 
SC-U + 
NaOH 
Initial 
PH 
6-6.5 
5-5.5 
7-7.5 
After 
48 h 
6-6.5 
5.0 
4.5 
Farnesol/ 
Nerolidol 
16.9 
1.22 
18.4 
It was previously thought that phosphatases were partially responsible for 
hydrolysis, and the PMY2 results reported here show that DPP1 has modest activity. A 
truncated alkaline phosphatase was isolated from & cerevisiae that hydrolyzed FPP to 
farnesol,77 and Poulter and Rilling138 reported prenyltransferases capable of hydrolyzing 
geranyl diphosphate to the corresponding alcohols and hydrocarbons. It remains possible 
that another enzyme promotes FPP hydrolysis, but this work demonstrates that a majority 
of FPP hydrolysis is non-enzymatic. 
These experiments establish that the pH of the medium influences whether FPP is 
hydrolyzed by SN2 or SN'1/ SN2' reactions. Acid in the medium probably does not directly 
catalyze the hydrolysis of intracellular FPP. Proton pumps prohibit the free diffusion of 
acid into the cell and intracellular pH is consequently rather independent of media pH. It 
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is conceivable that phosphatases are regulated by extracellular acid and therefore the 
enzymatic product profile depends on the acidity of the culture. However, this model 
would mandate that the phosphatase active site that generates nerolidol is electronically 
and sterically symmetrical, and it is difficult to conceive of a sufficiently strong selective 
pressure to promote racemic biosynthesis in this system. That the nerolidol is racemic is 
most readily explained by it being a nonenzymatic product arising from FPP being 
transported to the medium and undergoing an extracellular acid-mediated SNI reaction at 
the tertiary allylic center. 
To test for the presence of minor sesquiterpene compounds and to provide further 
insights into the hydrolysis mechanisms, PMYl[pRS316Gal] products were purified by 
column chromatography with pentane and a mixture of pentane/ether (5:1). These 
fractions were analyzed by GC-MS and NMR, and several minor products were 
discovered (Figure 4.5). 
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Figure 4.5. Total ion chromatogram of the PMYl[pRS316Gal] fraction containing 
nerolidol, a-bisabolol, and farnesal. The 10.1 to 10.8 minute range was expanded 20 
times to show the minor compounds. PMYl[pRS316Gal] was grown in SC-U. 
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GC-MS analysis revealed a sesquiterpene alcohol peak at 10.2 min that had a 
retention time and fragmentation patterns that matched an authentic standard of <x-
bisabolol (See Appendix D for mass spectral data). lH NMR analysis confirmed the 
structure and indicated a pair of diastereomers. Limited amounts of material precluded 
chiral NMR studies to establish whether a-bisabolol was racemic or chiral. Previously, 
Carrau et al. reported that S. cerevisiae generates the monoterpene cyclic alcohol a-
terpineol in under similar conditions,139 suggesting non-enzymatic hydrolysis of geranyl 
pyrophosphate (GPP). a-Bisabolol most likely is derived from a similar mechanism using 
FPP. Hydrolysis of FPP or nerolidyl pyrophosphate (NPP) had been implicated 
previously in production of a-bisabolol in the cotton 8-cadinene synthase, where it was a 
minor enzymatic product.140 
In addition, the pentane fractions showed two olefinic elimination products, a-
and P-farnesenes, as established by comparison of the mass spectral patterns with those of 
authentic standards (See Appendix D for mass spectral data of farnesene). These 
compounds could form either through an El or an E2 elimination mechanism. These 
results demonstrate a complex product profile, with solvolysis leading to both 
substitution and elimination products. Additionally, farnesal and famesyl acetate were 
also detected, based on their mass spectral patterns. These are readily rationalized as 
oxidized or acetylated metabolites of farnesol. Farnesyl acetate had a retention time and 
mass spectrum matching that of an authentic standard, while the farnesal mass spectrum 
was compared to that found in literature.141 These minor components were found in very 
small levels, providing less than 2% of the product profile (Table 4.4). a-Bisabolol was 
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present at approximately 1%, whereas famesal, farnesyl acetate, and farnesenes were 
found at levels less than 0.1%. 
Table 4.4. Sesquiterpene products isolated from PMYl[pRS316Gal] grown in SC-U. 
Compound 
Nerolidol 
Farnesol 
a-Bisabolol 
Farnesenes 
Farnesyl acetate 
Farnesal 
% Composition 
59.5% 
39.5% 
1.05% 
0.08% 
0.03% 
0.02% 
Figure 4.6 shows how the C15H26O and C15H24 products are accessible upon 
ionization the farnesyl cation, which can be quenched at the primary or tertiary allylic 
positions to give farnesol and nerolidol, respectively. The a-bisabolol diastereomers arise 
from cation-olefin cyclization, followed by quenching through an Sjvjl-type mechanism. 
Products a-farnesene and P-farnesene could be generated from deprotonation through an 
El mechanism. Farnesal and farnesyl acetate are derived separately from farnesol. 
Figure 4.6. Proposed mechanism of PMYl[pRS316Gal] products from non-enzymatic 
FPP hydrolysis. SNI mechanisms lead to formation of farnesol, nerolidol, or bisabolol. a-
Farnesene and P-farnesene could arise from El mechanisms. 
However, Figure 4.6 is a simplification. It is difficult to envision a-bisabolol 
being formed by a process other than initial ionization, but alternative reasonable origins 
for other structures probably contribute to the product profile. The level of the primary 
alcohol farnesol is much too high for a pure SNI mechanism. Much of the farnesol 
probably arises from SN2 attack, and an SN2'-type reaction could form nerolidol, with 
water attacking at C-3. Some of the farnesol could arise from hydrolysis of the phosphate 
ester by nucleophilic attack on the a-phosphate. A bimolecular elimination could also 
occur to give a- and P-farnesenes through an E2 mechanism. 
All of these processes can be envisioned as non-enzymatic reactions in the media, 
but only the argument for nerolidol is strongest because it was demonstrated to be 
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racemic. Although whether a-bisabolol is chiral could not be determined, its 
diastereomeric ratio and poor yields are consistent with non-enzymatic cyclization. 
Farnesol and the farnesenes are achiral and their structures consequently do not 
illuminate the fractions that are enzymatic or nonenzymatic in origin. 
The extent to which enzymatic origins could contribute to the product profile can 
be considered in light of known enzymes and S. cerevisiae genomic sequence. The 
genome encodes other phosphatases which could generate farnesol. However, yeast 
lacks obvious homologs of known enzymes that generate farnesenes or a-bisabolol. 
Farnesenes can be rationalized as potential minor products of prenyl transferases or 
squalene synthase, which are known yeast enzymes that generate the farnesyl cation. 
Farnesenes seem likely by-products of processes that use the farnesyl cation, however the 
low levels produced here suggest that farnesenes may have evaded detection in previous 
work. That a-bisabolol could be a minor product of prenyltransferases seems less likely, 
because cyclization requires a coiled conformation that seems inaccessible in the 
extended active sites of these enzymes. 
Metabolically engineered yeast are now used for commercial farnesol production, 
and the experiments described above establish that media manipulation can generate 
nerolidol. Farnesol and nerolidol are valuable compounds for the cosmetic and fragrance 
industries, and these alcohols have been used to enhance transdermal delivery of several 
drugs.142'143 Additionally, farnesol and nerolidol have shown antimicrobial and limited 
antitumor activity.144"148 These strains can be utilized to produce large amounts of these 
linear alcohols. 
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The discovery of substantial levels of non-enzymatic hydrolysis has substantial 
implications for sesquiterpene metabolic engineering. Metabolic engineering efforts to 
synthesize sesquiterpenes have focused on increasing accumulation of the FPP substrate. 
Manipulation of the yeast sterol biosynthetic pathway has produced sufficient FPP to aid 
in characterization of numerous sesquiterpene synthases, the enzymes that catalyze FPP 
cyclization, and P450 oxidases which further metabolize the hydrocarbon products.88'131'149 
Deletion of squalene synthase dramatically increased the amounts of sesquiterpene 
products isolated, but FPP hydrolysis still represents a large sink for FPP. Takahashi et 
al. previously established that expressing a terpene synthase in a DPP1 deletion does not 
substantially improvement in cyclization yields. As shown above, neither DPP1 nor 
LPP1 deletion fundamentally alters FPP hydrolysis. 
In metabolically engineered processes intended to biosynthesize cyclic terpenoids, 
FPP hydrolysis is a major competing outcome to cyclization. The experiments described 
herein point to severe limitations in abolishing FPP hydrolysis, suggesting that improving 
the efficiency of sesquiterpene synthases by improved expression technology or catalytic 
properties might be the next step needed to improve sesquiterpene cyclization yields. 
The work presented here demonstrates a facile approach to altering media pH to 
preferentially generate farnesol or nerolidol as the major product. Deletion of DPP1 could 
aid in efforts to decrease the competing reaction of FPP hydrolysis, however, farnesol 
and nerolidol production cannot be completely abolished through phosphatase deletion 
alone. 
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Experimental Procedures 
Construction of yeast strains. The yeast strains PMY1 and PMY2 were 
constructed by fellow graduate student Pietro Morlacchi. The BEJY14 strain was 
constructed by former lab member Dr. Beth Jackson.150 PMY1 was transformed with the 
yeast expression vector pRS316Gal to yield a control strain PMYl[pRS316Gal] that 
grew on synthetic complete medium lacking uracil (SC-U). 
Growth and isolation of sesquiterpene products from culture media. Single 
yeast colonies were used to inoculate 10-mL dextrose cultures of either YP (PMY1, 
PMY2, or BEJY14) or SC-U (PMYl[pRS316Gal]). Because these strains did not have 
intact sterol biosynthetic pathways, cultures were supplemented with heme and 
ergosterol. Galactose cultures (100 mL) were inoculated with the saturated 10-mL 
dextrose cultures. Once saturated, these cultures were transferred to 250-mL flasks 
containing methanol-activated hydrophobic resin (Diaion-20, Supelco) and were 
incubated at 30 °C with shaking overnight. Cultures were filtered through Kontes 
columns and the cells and media were set aside. The resin remaining in the column was 
washed with 3 volumes of ethanol and the internal standard longifolene (100 ug) was 
added to the extracts. The ethanol was then partitioned between one-half volume of water 
and three one-half volumes of pentane. The combined pentane extracts were concentrated 
by rotary evaporation and transferred to GC vials with 1 mL pentane. Ten percent of each 
extract was used for GC-MS and GC-FID analysis. The peak areas of farnesol and 
nerolidol were compared to that of longifolene to determine the amount of products 
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isolated from each culture. Triplicate cultures ensured more accurate numbers were 
obtained. 
Isolation of sesquiterpenes from cell pellets. The 100-mL galactose cultures 
used for resin extractions were centrifuged (3000 rpm, 10 min) after filtering through the 
Kontes columns. The resulting cell pellets were subjected to saponification in 5 mL 10% 
KOH in 80% EtOH with 200 mg BHT (butylated hydroxytoluene, an antioxidant). The 
solutions were heated in a 70 °C water bath for 2 h and allowed to cool to room 
temperature. Distilled H2O (5 mL) was added and the solutions were extracted with 3 * 
15 mL pentane, and the solvent was then removed in vacuo. The residues were 
transferred to GC vials with 1 mL pentane and 100 ug longifolene was added prior to 
analysis by GC-MS and GC-FID. 
Isolation of minor products in PMYl[pRS316Gal]. A 1-L galactose culture of 
PMYl[pRS316Gai] was grown in SC-U and the organic compounds were isolated as 
described above. The resin extract was chromatographed over a silica gel column using a 
5:1 pentane/ether mixture. Finally 100% ether was used to elute any remaining 
compounds. Each fraction was analyzed by TLC and GC-MS, and possible minor 
products were tentatively identified. 
Determination of nerolidol stereochemistry using a chiral shift reagent. A 
lanthanide chiral shift reagent was utilized to determine its effect on lH NMR chemical 
shifts of the nerolidol product, following the protocol outlined by Wilson et al.134 The 
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alcohol group in linalool has the same steric and electronic environment as nerolidol, and 
linalool standards were first tested to determine how the reagent affects the chemical 
shifts. 
Europium tris[2-(heptafluropropylhydroxymethylene)-(+)-camphorate] (Eu(hfc)3) 
was diluted to a 4.7 nM solution in CDCI3 and was slowly added to the racemic linalool 
standard. As more Eu(hfc)3 was added, the peaks began shifting downfield and split the 
enantiomers. By adding (-)-linalool standard (Fluka), we were able to overlay signals for 
the shifted enantiomer. 
A racemic nerolidol standard (Sigma) was also tested in this system to ensure that 
it had the same behavior as the linalool standard, and the olefinic peaks did indeed shift 
further downfield and split slightly when shift reagent was added. The nerolidol isolated 
and purified from the yeast was diluted in CDCI3 and analyzed by 'H NMR prior to 
addition of the shift reagent. Eu(hfc)3 was slowly added and the olefinic peaks were 
shifted from 5.232 ppm to 5.462 ppm. 
Culture media effects on sesquiterpene production. The yeast strains PMY1 
and PMYl[pRS316Gal] were grown in galactose with different nitrogen sources to 
determine whether or not media composition played a role in FPP hydrolysis. PMY1 was 
grown in rich medium (YP) and PMYl[pRS316Gal] was grown in synthetic medium 
(SC-U), a 1:1 mixture of YP and SC-U, or SC-U supplemented with either yeast extract 
or peptone. Once saturated, the cultures were transferred to activated resin and 
extractions were carried out as described above. The media extracts were quantitated by 
GC-FID. 
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Media pH effects on sesquiterpene production. Looking at the pH at various 
points between inoculation and saturation of the cultures and the corresponding controls 
provided a more comprehensive idea of how pH changed with incubation time. 
Galactose cultures (50 mL) were inoculated from dextrose cultures, and 50-mL galactose 
control cultures containing no yeast were also prepared. pH measurements were recorded 
at time of inoculation and after 30 and 48 hours incubation. Cultures were then harvested 
and resin was extracted as described above. 
An experiment to decrease the acidity of YP to that of SC-U was then carried out. 
A 100-mL galactose culture of YP was prepared, and NaH2P04 was added for a final 
concentration of 180 mM to decrease the pH of the media to approximately 5.5. Another 
100-mL YPGHE culture was prepared, and MOPS (buffering range pH 6.5-7.9) was 
added to a final concentration of 50 mM, with pH measured at 6.5-7.0. Alternatively, the 
pH of a 100-mL YPGHE culture was adjusted to 5.0-5.5 with the addition of glacial 
acetic acid. pH of these cultures was monitored over the incubation time. 
Additionally the pH of SC-U was increased to mimic that of YP. First, a small 
amount of NaOH was added to 50 mL SCG-UHE prior to inoculation with 
PMYl[pRS316Gal]. The pH of the culture increased from 5.5 (prior to NaOH addition) 
to 7.0-7.5 (after addition). Another 50-mL culture of PMYl[pRS316Gal] was grown in 
SCG-UHE after addition of a small pellet of NaOH and 1 g MOPS buffer, with the pH 
increasing from 5.5 to 6.0-6.5. Finally, a 50-mL culture was supplemented with 5 M 
NaOH to pH 7.0-7.5. pH of all cultures was monitored throughout incubation and at the 
time of harvesting. 
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Characterization of (±)-(65',75)-a-bisabolol and (±)-(6£,71?)a-bisabolol. lH 
NMR spectra were measured on a Varian 800 MHz spectrometer. The a-bisabolol !H 
NMR chemical shifts matched those reported in literature.151 
Table 4.5. (±)-(61S',75)-a-Bisabolol !H NMR chemical shifts, comparing literature and 
observed values. An asterisk indicates the peak was partially covered by a nerolidol peak 
so accurate values could not be determined. 
Atom# 
H-2 
H-10 
H-12 
C-3Me 
C-7Me 
C-ll 
Literature value 
5.37 (br s) 
5.12 (t, 7 = 7 Hz) 
1.68 
1.64 
1.10 
1.62 
Observed value 
5.375, m 
5.131, t,J = 7.1, 1.4-Hz 
1.68* 
1.652 
1.110 
1.620 
Table 4.6. (±)-(6S,7i?)-a-Bisabolol ]H NMR chemical shifts, comparing literature and 
observed values. An asterisk indicates the peak was partially covered by a nerolidol peak 
so accurate values could not be determined. 
Atom# 
H-2 
H-10 
H-12 
C-3Me 
C-7Me 
C-ll 
Literature value 
5.39 (br s) 
5.12 (t, 7 = 7 Hz) 
1.68 
1.64 
1.13 
1.62 
Observed value 
5.39, m 
5.131, t, J = 7.1, 1.4 Hz 
1.68* 
1.652 
1.139 
1.620 
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Chapter 5 
Accumulation of triterpene substrates oxidosqualene and 
dioxidosqualene 
Introduction 
Triterpenoids are derived from three different acyclic 30-carbon precursors -
squalene, oxidosqualene (OS), or dioxidosqualene (DOS).152 S. cerevisiae produces all 
three of these compounds, and squalene and OS are intermediates in the sterol 
biosynthetic pathway (Figure 5.1). Squalene is oxidized by squalene epoxidase (ERG1) 
to form (35)-oxidosqualene.43 When yeast with a native sterol biosynthetic pathway 
experience normal vegetative growth, oxidosqualene does not accumulate to any 
appreciable extent but is cyclized by lanosterol synthase (ERG7) to lanosterol, the first 
committed intermediate in sterol biosynthesis. When lanosterol synthase activity 
becomes limiting, OS can accumulate and then re-enter the ERG1 active site for further 
epoxidation. The resultant molecule (35',225)-dioxidosqualene50 is not utilized in the 
formation of ergosterol but is an intermediate in the production of epoxysterols, which 
play a regulatory role in sterol biosynthesis.55 
H O O C ^ ^ X ^ C O S C o A 
HMGCoA 
oxidosqualene 
ERG1 
HMGR «. PH 
HOOC-. 
mevalonic acid 
lanosterol 
HO' 
ergosterol 
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Figure 5.1. Yeast sterol biosynthetic pathway and formation of DOS. ERG1 epoxidizes 
squalene to form OS, which can then re-enter the active site to produce DOS. 
Results and Discussion 
Lanosterol synthase mutants such as SMY8120 have been the preferred expression 
hosts for in vivo and in vitro systems to biosynthesize triterpenes.98'99'101'102'153 The 
absence of lanosterol synthase abolishes native cyclization to promote the accumulation 
of OS. Two SMY8 derivatives were constructed in an attempt to increase accumulation 
of the triterpene precursors OS and DOS. The yeast strain ABY1 was generated by 
overexpressing a solubilized form of HMG-CoA reductase (trHMGl)82 in SMY8 to 
increase carbon flux through the biosynthetic pathway (Table 5.1). To promote DOS 
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rather than OS biosynthesis, we constructed a strain (ABY2) that overexpressed the yeast 
squalene epoxidase ERG1. 
Table 5.1. Summary of constructed yeast strains. All strains are MATa and erg7::HIS3 
heml::TKPl ura3-52 trpl-A63 his3-A200 adel GAL+. 
Strain 
SMY8rpRS305Gall 
ABY1 
ABY2 
Characteristics 
Control strain 
trHMGl::LEU2 
ERG1::LEU2 
The ability of these strains to accumulate acyclic triterpenoids was investigated 
using galactose as the carbon source. The SMY8 parent and the two derivative strains 
biosynthesize the triterpene precursors squalene, OS, and DOS without need for inducing 
medium. The genetic modifications that yielded ABY1 and ABY2 are driven by 
galactose-inducible promoters and thus required galactose to induce expression. The 
SMY8[pRS305Gal] control was also induced with galactose to ensure consistency 
between cultures. The amount of inoculum can be important. Excessively large inocula 
give poorer yields because of insufficient generations in inducing medium, whereas 
insufficient inocula can yield cultures that grow so long under inducing conditions that 
poorly-expressing mutant derivatives (which can have a selective advantage) can take 
over the culture. A 1% inoculum struck a good balance. 
For each strain, cultures were harvested at log-phase and the cell pellets were 
saponified and extracted. The resulting non-saponifiable lipids (NSL) were TMS-
derivatized overnight and quantitated by GC-FID, with the peak areas of squalene, OS, 
and DOS compared to that of TMS-epicoprostanol as internal standard (Table 5.2). 
Several observations were made from the cell pellet data. SMY8[pRS305Gal] served as 
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the control strain, producing 0.5 mg/L total triterpenes, with four times more DOS than 
OS produced. On the other hand, ABY1 accumulated twice as much OS as DOS with 10 
mg/L total linear triterpenes. This strain was dramatically different than the other two 
strains, as it was the only strain producing more OS than DOS. 
Table 5.2. Quantitation of NSL based on GC-FID integration. Product areas were 
compared to that of TMS-epicoprostanol. Each yield was based on triplicate cultures. 
N.D. indicates the product was <1% of the major product. 
Strain 
SMY8rpRS305Gall 
ABY1 
ABY2 
Squalene 
(mg/L) 
N.D. 
0.35 ± 0.05 
N.D. 
OS 
(mg/L) 
0.11 ±0.03 
6.78 ± 0.56 
0.04 ± 0.01 
DOS 
(mg/L) 
0.41 ±0.10 
3.39 ±0.35 
0.19 ±0.01 
DOS/ 
OS 
3.70 
0.50 
5.04 
trHMGl overexpression sharply increased the production of acyclic triterpenes; 
the ABY1 strain accumulated approximately 20 times more squalene and derivatives than 
did SMY8. This strong effect confirms that mevalonate production limits OS biosynthesis 
in SMY8. The decreased DOS/OS ratio in ABY1 is readily rationalized in light of the 
introduced changes. The overexpression of trHMGl introduces more carbon into the 
sterol biosynthetic pathway and thereby promotes squalene biosynthesis. The influx of 
new squalene apparently exceeds the native ability of squalene epoxidase to consume it, 
and a substantial portion of the total material resides as the monoexpoxide. 
ERG1 overexpression had modest influence on OS and DOS production during 
log-phase. The ABY2 strain had a slightly higher DOS/OS ratio (5:1), compared to 
SMY8[pRS305Gal](4:l). 
To investigate whether triterpenes were secreted into the culture medium, the log-
phase culture media were extracted and the acyclic products were quantitated by GC-FID 
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(Table 5.3). The data showed that the squalene derivatives accumulated in the media at 
levels up to five times higher than that isolated from the cell pellets. From this data, the 
more polar DOS appears to be preferentially secreted into the medium instead of OS. 
Because of this, the results described for the cell pellets were not a comprehensive 
enough picture for the roles of trHMGl and ERG1 overexpression in SMY8. 
Table 5.3. Quantitation of media extracts based on GC-FID integration. Product areas 
were compared to that of TMS-epicoprostanol. Each yield was based on triplicate 
cultures. N.D. indicates squalene was not detected within a 1% detection limit. 
Strain 
SMY8rpRS305Gall 
ABY1 
ABY2 
Squalene 
(mg/L) 
N.D. 
N.D. 
N.D. 
OS 
(mg/L) 
0.16±0.03 
0.12±0.02 
0.03±0.01 
DOS 
(mg/L) 
1.05±0.24 
1.25±0.11 
1.65±0.28 
DOS/ 
OS 
6.59 
10.6 
61.7 
The media from SMY8[pRS305Gal] and ABY1 cultures contained similar 
amounts of OS and DOS, with about 1.3 mg/L total triterpenes isolated from both strains. 
Therefore the cell pellet data is more definitive in understanding the role of trHMGl 
overexpression on squalene derivative biosynthesis. The ABY2 strain overexpressing 
ERG1 accumulates more DOS and less OS in the medium than the parent strains does, 
with a DOS/OS ratio 10 times higher than that of SMY8. From these results the media 
illuminated the effect of ERG 1 overexpression more strongly than the cell pellet data. 
In order to better understand the trends between the three strains, the total 
amounts of triterpenes produced by these strains were calculated by combining the cell 
pellet and media data (Table 5.4), which show substantial differences between the 
engineered strains and the parent SMY8 strain. ABY1 accumulated the most triterpene 
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precursors, with nearly 12 mg/L total triterpenes, whereas SMY8[pRS305Gal] and ABY2 
accumulated similar amounts of OS and DOS. 
Table 5.4. Total triterpenes from each strain, isolated from both cell pellets and media. 
Quantitation is based on GC-FID integration and numbers are reported in mg/L. 
Strain 
SMY8rpRS305Gall 
ABY1 
ABY2 
Squalene 
(mg/L) 
0.04±0.02 
0.35±0.05 
N.D. 
OS 
(mg/L) 
0.28±0.05 
6.90±0.56 
0.06±0.01 
DOS 
(mg/L) 
1.59±0.28 
4.68±0.27 
1.83±0.29 
DOS/ 
OS 
5.65 
0.68 
28.2 
The three strains exhibited significant differences in DOS/OS ratios. ABY1 
produced almost twice as much OS than DOS. The other two strains produced more DOS 
than OS, with SMY8 having the smaller ratio. ABY2 has the largest DOS/OS ratio of the 
three strains, as intended; its overexpressed ERG1 facilitates the oxidation of OS to DOS. 
In addition to the log-phase measurements, cultures were also harvested at 
saturation and the acyclic precursors were quantitated. Media and cell pellets from 
SMY8[pRS305Gal], ABY1, and ABY2 were studied, and the results were quite different 
from those observed in the log-phase cultures. The cell pellet data was consistent among 
all strains, with ratios of DOS/OS comparable between log-phase and saturation cultures. 
The media extracts again contained a majority of the acyclic compounds and 
demonstrated an increase in DOS production over incubation time. 
Lengthening culture times increased the DOS/OS ratios because precursor 
biosynthesis stops when carbon is exhausted, but oxidation continues. The amount of 
acyclic precursor per liter and the DOS/OS ratios remain similar throughout log-phase 
SMY8[pRS305Gal] growth. The final culture was harvested after saturation, resulting in 
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the largest cell pellet and the largest DOS/OS ratio. The greater mass of acyclic 
triterpenes at saturation indicates that the 30-carbon molecules were converted from 
earlier precursors (e.g., FPP or squalene) at saturation (Figure 5.2). Over time more DOS 
was produced in the strain, increasing the DOS/OS ratio and indicating that further 
oxidation took place after saturation. 
3.00 
0.34 0.50 
Cell pellet (g) 
Figure 5.2. GC-FID quantitation of SMY8[pRS305Gal] media extracts harvested at 
varied growth stages. Cultures ranged from one day growth (0.34 g) to log-phase (0.50 g) 
to saturation (1.14 g). The black columns represent OS production in mg/L, while the 
patterned columns represent DOS production in mg/L. 
Similar results were observed with ABY2 (Figure 5.3), as increasing amounts of 
DOS accumulated as cultures were incubated longer. The amount of OS also decreased 
with incubation time, further increasing the DOS/OS ratio. Because the cultures were 
inoculated from dextrose-containing cultures, galactose induction did not occur 
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immediately.154 Once the dextrose was consumed, galactose was utilized by the yeast and 
the ERG1 gene was finally turned on to produce more OS and DOS. Harvesting cultures 
too early, as shown in the first culture, meant less material was isolated from the early 
culture. 
Comparing the results from SMY8[pRS305Gal] and ABY2, the 
SMY8[pRS305Gal] cultures were allowed to incubate longer and thus had a larger 
amount of total triterpenes, in comparison to the ABY2 cultures. ABY2 accumulated 
almost 2 mg/L OS and DOS, while SMY8[pRS305Gal] produced nearly 3 mg/L, likely 
explained in the longer incubation time. 
2.00 
1.60 
1.20 
E 
0.80 
0.40 
0.00 
0.62 
Cell pellet (g) 
Figure 5.3. ABY2 media extract quantitation data from cultures harvested at different 
growth stages. The first culture was harvested after only one day, while the 0.62 g cell 
pellet was from a 2-day growth period (log-phase). The 0.76 g cell pellet was obtained 
after 3 days growth (saturation). The black columns represent OS production (mg/L) 
while the patterned columns represent DOS accumulation (mg/L). 
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Finally, the medium from the ABY1 strain was studied, and again the amount of 
DOS increased over a longer incubation time (Figure 5.4). Unlike the other strains, 
ABY1 had an increase in both OS and DOS over time. Additionally, at log-phase the 
amount of triterpenes accumulating was nine times lower than that observed for the 
saturated culture. The final culture harvested accumulated nearly 10 mg/L total 
triterpenes, the most isolated from any of these strains at any growth stage. 
10.0 
O) 
E 
0.74 0.87 
Cell pellet (g) 
1.08 
Figure 5.4. GC-FID quantitation data for ABY1 cultures harvested after different 
incubation times. The first two (0.74 g and 0.87 g) were harvested during log-phase, 
while the 1.08 g cell pellet is from a saturated culture after 3 days growth. Black indicates 
OS accumulation (mg/L) while the patterned columns represent DOS isolated from the 
media (mg/L). 
Careful consideration must be given to which growth stages of the yeast to 
examine to best understand the implications of manipulating these enzymes. It is 
relatively difficult to draw conclusions from OS/DOS ratios at saturation because OS can 
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re-enter the ERG 1 active site and be epoxidized on its distal terminus to convert OS to 
DOS. More DOS accumulated the longer cultures were allowed to incubate, thus the 
longer incubation time skewed the DOS/OS ratios of the yeast strains, with more DOS 
isolated than that observed in the log-phase cultures. Log-phase cultures are consequently 
essential in establishing the relevance of ERG1 and trHMGl to metabolic engineering 
conditions in which those the acyclic precursors would be cyclized in vivo. However, 
these log-phase cultures do not give a clear understanding of the ultimate amounts that 
could accumulate in a metabolically engineered system as would be seen if the material 
were harvested at saturation; the cell mass is less than a saturated culture, and the product 
yields are also low due to a lag-time in galactose induction. Quantitation of saturated 
cultures are therefore necessary for determining the total amounts of squalene derivatives 
the strains are capable of producing. 
Previously, most triterpene studies focused on triterpene products accumulating 
within the cells. This work demonstrates the necessity of studying the culture media, as 
up to 10 times more products were isolated from the media compared to the cell pellets. 
The full potential of the ABY2 strain was studied by growing triplicate 1-L 
cultures in optimized conditions described previously155 and harvesting at saturation. 
Because the ERG1 overexpression cassette was integrated, plasmid selection was not 
necessary and cultures could be grown in rich medium (YP with 2% adenine and 4% 
galactose). These nitrogen source optimizations coupled with higher galactose 
concentration provided greater cell mass and consequently more OS and DOS were 
produced from each culture. To quantitate the DOS isolated from the resin, the peak areas 
of DOS and TMS-epicoprostanol from GC-FID analysis were compared. The 
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optimization increased DOS yield 10-fold compared to the 100-mL cultures, yielding 
17.0 ± 0.9 mg/L DOS and 0.4 ± 0.1 mg/L of OS. This gave a DOS/OS ratio of 46.2. 
To obtain the most accurate quantitation results, specific structural properties of 
the acyclic triterpenes needed to be considered. OS and DOS are difficult to discriminate 
between (and consequently, to quantitate) by 'H NMR because both have epoxide termini 
with essentially indistinguishable *H NMR signals. Similarly, squalene and OS share 
olefinic termini with very similar *H NMR signals. GC-based analyses of these 
compounds could be complicated by the limited thermal stability of the strained epoxides 
on the GC column, and that they may not have GC-FID and GC-MS responses identical 
to that of epicoprostanol. In order to determine what, if any, effect the structure of the 
compounds could have on the quantitation results, mixtures of standards were prepared 
(in 1:1 ratios in xylenes) and analyzed by GC-FID, GC-MS, and 'H NMR. Six mixtures 
were prepared: squalene + OS, squalene + DOS, squalene + epicoprostanol, OS + DOS, 
OS + epicoprostanol, and DOS + epicoprostanol. 
Because the yeast extracts were quantitated on the GC-FID by comparing peak 
areas of the products to the peak area of TMS-epicoprostanol (abbreviated as TMS-epi), 
the mixtures of standards were derivatized and analyzed by GC-FID to determine the 
relative responses of squalene, OS, DOS, and epicoprostanol (Table 5.5). Also essential 
was to determine how derivatization affects the FID response. The trends were verified 
by analyzing the same samples on GC-MS. TMS-derivatization converts the alcohol 
moiety in epicoprostanol to the corresponding TMS-ether (Figure 5.5), making the 
compound more volatile and preventing much of the tailing observed in non-derivatized 
triterpene alcohols. This tailing prevents accurate integration of the epicoprostanol peak, 
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skewing the results. TMS-derivatization adds a silicon atom and three methyl groups, and 
it was essential to establish how this change would affect FID response. In addition, it 
was not known whether the reagents used for TMS-derivatization would affect OS or 
DOS. Although these compounds do not contain the necessary alcohol groups, it is 
conceivable that TMS-derivatization conditions could lead to OS and DOS degradation, 
or that the epoxides would thermally decompose on the column. The mixtures not 
containing epicoprostanol were derivatized as well to study what, if any, effect could 
occur. 
pyridine 
TMSCf 
Figure 5.5. TMS-derivatization of epicoprostanol. 
Table 5.5. GC-FID quantitation of triterpene standards before and after derivatization. 
Mixture 
Squalene/TMS-epi 
OS/Squalene 
OS/TMS-epi 
DOS/TMS-epi 
DOS/Squalene 
DOS/OS 
Before TMS-
derivatization 
0.99 
1.16 
1.10 
0.85 
0.88 
0.78 
After TMS-
derivatization 
0.75 
1,11 
0.83 
0.63 
0.86 
0.77 
Percent 
difference 
-24% 
+4.0% 
-25% 
-26% 
+2.3% 
+1.3% 
Effect on 
quantitation 
ratio 
Enhances 
Negligible 
Enhances 
Enhances 
Negligible 
Negligible 
The effect of derivatization was insignificant for the linear triterpenes, as the 
ratios of OS/squalene, DOS/squalene, and DOS/OS only increased 2-4% compared to the 
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non-derivatized ratios. The higher ratios observed for these three mixtures could be 
attributed to small amounts of degradation from the derivatization procedure. 
The mixtures containing epicoprostanol, on the other hand, showed dramatically 
different ratios when comparing non-derivatized to derivatized samples, with all ratios 
decreasing 25% compared to the non-derivatized ratio. TMS-epicoprostanol produced a 
much sharper peak on GC-FID and GC-MS, with less peak tailing, which made peak 
integration much more accurate than non-derivatized epicoprostanol. Additionally, the 
TMS-epicoprostanol has more atoms per sample than non-derivatized epicoprostanol, 
dramatically changing the FID response. The TMS-derivatized samples were used for all 
quantitation experiments. Because of the large differences in the ratios, however, a 
correction factor was necessary to provide the most accurate numbers. 
To verify these results, the same samples were analyzed by 600 MHz 'H NMR. 
Comparisons were made primarily in the upfield methyl regions (see experimental 
procedures for chemical shift information). NMR integration did not provide definitive 
ratios for all mixtures due to contaminations present in some samples causing inaccurate 
integration. However, the squalene/DOS and DOS/epicoprostanol mixtures gave clear 
results that were consistent with the initial mass measurements and were used as a 
standard with which to develop conversion factors for the GC-FID results (Table 5.6). 
Based on these two analytical methods, we determined that the epoxide moiety in DOS is 
not appreciably decomposed by the derivatization reagents or by 30 min exposure to the 
260 °C column. Squalene, OS, and DOS do not have substantial differences in thermal 
stability on GC-FID, and their FID responses are within experimental error of one 
another. 
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Table 5.6. Comparison of ratios determined from GC-FID and *H NMR. 
Mixture 
DOS/squalene 
DOS/epicoprostanol 
Before TMS-
derivatization 
0.88 
0.854 
After TMS-
derivatization 
0.86 
0.628 
NMR 
calculated 
ratio 
0.90 
0.83 
Final 
correction 
factor 
Negligible 
1.32 
The amounts of DOS were thus recalculated for each yeast strain, taking the 
correction factor into account. Minor experimental errors, such as weighing (~2% error) 
and measuring of solvents (~1%) were not included in the correction factors, as these 
issues were present for all samples prepared. GC-FID, GC-MS, and NMR analyses 
revealed impurities in squalene, OS, DOS, and epicoprostanol. OS had <1% impurities 
whereas the other three standards contained approximately 5% impurities. These were 
accounted for in a correction factor. First, the NSL values from the log-phase cultures 
were recalculated (Table 5.7). The media extracts were similarly recalculated (Table 5.8). 
Table 5.7. Corrected quantitation data of log-phase NSL. Results are based on GC-FID 
integration, with product areas compared to that of TMS-epicoprostanol. Each yield was 
based on triplicate cultures and includes a correction factor (Linear triterpenes/TMS-
epicoprostanol = 1.32). 
Strain 
SMY8rpRS305Gall 
ABY1 
ABY2 
Squalene 
(mg/L) 
N.D. 
0.46 ± 0.07 
N.D. 
OS 
(mg/L) 
0.15 ±0.04 
8.95 ± 0.74 
0.05 ±0.01 
DOS 
(mg/L) 
0.54 ±0.13 
4.48 ± 0.46 
0.25 ±0.01 
DOS/ 
OS 
5.34 
0.50 
5.39 
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Table 5.8. Corrected quantitation values for media extracts. Quantitation was based on 
GC-FID integration. Product areas were compared to that of TMS-epicoprostanol. Each 
yield was based on triplicate cultures and includes a correction factor (Linear 
triterpenes/TMS-epicoprostanol = 1.32). 
Strain 
SMY8rpRS305Gall 
ABY1 
ABY2 
Squalene 
(mg/L) 
0.02 ±0.01 
N.D. 
N.D. 
OS 
(mg/L) 
0.21 ± 0.04 
0.16 ±0.02 
0.04 ± 0.01 
DOS 
(mg/L) 
1.39 ±0.315 
2.18 ±0.187 
2.17 ±0.374 
DOS/ 
OS 
8.90 
14.3 
66.0 
It was also useful to study the effects of differing chemical functionalities present 
when measuring product accumulation, as demonstrated here. Squalene, OS, and DOS 
demonstrated similar behavior on GC-FID, whereas TMS-epicoprostanol had differences 
in integration caused by extra atoms and sharper peaks, and these were accounted for by 
including a correction factor. The same correction factor (1.32) was used to recalculate 
yields for both OS and DOS accumulation. 
While the correction factor did not change the DOS/OS ratios significantly, the 
correction did enhance the overall triterpene substrate yields. In the ABY1 strain, the 
total amount of OS and DOS accumulating in both the cell pellets and media was nearly 
17 mg/L, compared to the original calculation of almost 12 mg/L. ABY1 accumulated 
eight times more material than the parent SMY8 strain, which was recalculated to 
accumulate 2.3 mg/L of OS and DOS between the cell pellets and media. ABY2 still 
accumulated similar amounts of triterpene precursors compared to SMY8, but the 
DOS/OS ratio was slightly higher than that previously observed. 
The work presented here shows the remarkable potential of metabolic engineering 
for triterpene biosynthesis. By overexpressing the rate-limiting enzyme trHMGl in the 
SMY8 parent strain, the amounts of epoxidized triterpene substrates accumulating 
increased 10-fold, producing more OS and DOS than the parent strain. This is consistent 
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with previous data in which overexpression of trHMGl increased sesquiterpene and 
diterpene production.35'82 Overexpression of the yeast ERG1 did not increase the amount 
of substrate accumulating in comparison to SMY8, but the higher epoxidation capacity of 
ABY2 increased the DOS/OS ratio dramatically, with nearly 80 times more DOS 
observed than OS. 
The strains presented here produce large amounts of the triterpene substrates OS 
and DOS and are useful tools for studying OS or DOS cyclization. For example, the OS 
produced by ABY1 is the substrate for oxidosqualene cyclases (OSCs). Expression of 
OSCs in ABY1 would therefore facilitate the characterization of novel enzymes. The 
higher substrate levels should increase triterpene product yields, providing more material 
for structural identification. 
Additionally, OS and DOS can be accepted by many OSCs, including 
Saccharomyces lanosterol synthase,53'54 Arabidopsis thalianol synthase,153 and 
Arabidopsis lupeol synthase.103 Utilizing strains that can produce larger amounts of both 
precursors can therefore aid in characterization of products derived from both OS and 
DOS cyclization. Several epoxy triterpenes have been definitively or putatively identified 
as DOS cyclization products,153'156"159 and the wealth of products from this alternate 
substrate is still not fully realized. Epoxylanosterol and oxysterols play a role in sterol 
homeostasis in animals and fungi and have potential medicinal utility.160"162 Additionally 
these compounds could be utilized by plants as potential defense compounds. Improved 
means to uncover useful structures and interesting activities will expedite progress in 
these areas. 
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Experimental Procedures 
Construction of yeast strain ABY1. The plasmid pEH12.4, containing the N-
terminal truncated HMG1 gene82 in the yeast expression vector pRS305biGal, was made 
by former lab member Dr. Gia Fazio. This plasmid was linearized with BstE II and 
integrated into the lanosterol synthase mutant SMY8 at the Ieu2 locus using the lithium 
acetate method.119 Transformants were selected on synthetic complete medium lacking 
leucine, yielding the ABY1 yeast strain (MATa erg7::HIS3 heml.JRPl trHMGl:\LEU2 
ura3-52 trpl-A63 his3-A200 ade2 GAL+). 
Construction of ERG1 overexpression strain. The plasmid pGCF6.0 containing 
ScERGl, made by former member Dr. Gia Fazio, is in the integrative yeast expression 
vector pRS305Gal.155 The BsrG I-linearized plasmid was integrated into SMY8 at the 
leu2 locus, as discussed above. Transformants were selected on synthetic complete 
medium lacking leucine. The resulting strain was named ABY2 (MATa erg7::HIS3 
hemlv.TRPl ERG1::LEU2 ura3-52 trpl-A63 his3-A200 ade2 GAL+). 
Isolation of triterpenes from cell pellets. SCD-LeuHE cultures (10 mL) of 
SMY8[pRS305Gal], ABY1, and ABY2 were inoculated from single colonies and grown 
at 30 °C until saturated; these cultures (using 1 mL inocula) were used to start 100-mL 
SCG-LeuHE cultures. The galactose cultures were removed either in log-phase or once 
saturated, as determined by checking OD600 of each culture. Cultures were harvested by 
centrifugation; the media was set aside for further analysis. Each cell pellet was 
saponified in 10 mL 10% KOH in 80% ethanol. BHT (2 mg in ethanol) was added prior 
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to saponification, as well as the internal standard epicoprostanol (250 ug in ethanol) for 
quantitation. The mixture was incubated in a 70 °C water bath for 2 h and allowed to cool 
to room temperature. The NSL were extracted with 3 10-mL aliquots of hexanes, and the 
combined extracts were washed with 2 5-mL aliquots of distilled water before 
evaporation of solvent in vacuo. The residues were transferred to vials with small 
portions of hexanes. Ten percent of each extract was analyzed by GC-MS and GC-FID. 
Isolation of triterpene products from media. Hydrophobic resin was used to 
adsorb any organic materials present in the medium. The media from each culture was 
transferred to methanol-activated Diaion-20 resin (5 g) and allowed to incubate at 30 °C 
with shaking overnight. The resin-medium mixture was put through a Kontes column and 
the medium was allowed to drain. The resin was washed with 3 x 1 5 mL ethanol and the 
combined ethanol extracts were then partitioned with 20-mL diEkO and 3 15-mL aliquots 
of hexanes. The hexane extracts were washed with 2 x 5 mL diFbO prior to evaporation 
of solvent, as described above. Epicoprostanol (250 ug in ethanol) was added to the 
ethanolic extracts prior to hexane extractions as an internal standard. Ten percent of each 
extract was analyzed by GC-MS and GC-FID. 
TMS-derivatization of extracts. After initial GC-FID and GC-MS analysis, 
solvents from all samples were evaporated under a nitrogen stream and re-dissolved in 
100 uL pyridine and 100 uL BSTFA (bis(trimethylsilyl)trifluoroacetamide). Samples 
were incubated at 37 °C overnight and then analyzed by GC-FID and GC-MS. 
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Large-scale production of DOS. Three 1-L cultures were prepared with 10-mL 
inocula, using YP medium supplemented with 2% adenine and 4% galactose. These 
cultures were grown to saturation and harvested by centrifugation. The media from each 
culture was transferred to 15-g methanol-activated resin and incubated overnight at 30 
°C, while the cell pellet was saponified and the non-saponifiable lipids extracted with 3 x 
100 mL hexanes. The resin was eluted with ethanol and the ethanol partitioned with one-
half volume water and 3 x 100 mL hexanes. Epicoprostanol was added as internal 
standard prior to the extraction. All solvent was removed in vacuo. All samples were 
analyzed by GC-FID and GC-MS. 
DOS purification. DOS was purified from 2-L resin extracts of ABY2 by silica 
gel chromatography. The extracts were dissolved in 2% ether in hexanes and loaded onto 
a short column (containing 6 g silica gel). The first fractions, eluted with 2% ether in 
hexanes, contained squalene. OS was eluted with 4% ether and hexanes. DOS was found 
in fractions eluted with 6% ether in hexanes. GC-MS analysis of one fraction showed 
97% DOS and 3% epicoprostanol. 
Quantitation of triterpene standards by GC-FID. Four standards - squalene, 
OS, DOS, and epicoprostanol - were accurately weighed into glass vials (within 2% 
error) and left under the vacuum dessicator overnight. The samples were weighed again 
and dissolved in p-xylene to give 1.0 mg/mL stock solutions. Mixtures were prepared 
from the stock solutions, measuring 100 uL of each standard solution with a gas-tight 
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Hamilton syringe into a GC vial containing an insert. The six samples were then analyzed 
by GC-FID and GC-MS. 
TMS-derivatization of triterpene standards. After analysis, the GC samples 
were divided in half, with 100 uL set aside for NMR analysis. The remaining samples 
(100 uL) were placed under nitrogen streams to remove solvents and were then 
derivatized overnight (100 |JL pyridine + 100 |JL BSTFA). The TMS-derivatized samples 
were then analyzed by GC-FID and GC-MS. 
Quantitation of triterpene standards by NMR. Solvent from the remaining 
non-derivatized samples was evaporated under nitrogen. These samples were then put 
under vacuum overnight to remove as much solvent as possible and ultimately used for 
'H NMR analysis. The 600 MHz NMR was used, with 64 scans per sample. Integration 
of distinct methyl peaks (Figure 5.6 and Table 5.9) provided ratios. 
Figure 5.6. Structures of triterpene standards squalene, OS, DOS, and epicoprostanol. 
Circled methyl groups correspond to 1.60 ppm, and boxed methyl groups correspond to 
1.26 and 1.30 ppm. 
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Table 5.9. 'H NMR chemical shifts for the distinct methyl groups of squalene, OS, and 
DOS. For 1.26 ppm - 1.68 ppm, the number of methyls corresponding to each chemical 
shift are noted. 
Compound 
Squalene 
OS 
DOS 
1.26+1.30 
ppm 
0 
1+1 
2+2 
1.60 
ppm 
6 
4 
2 
1.62 
ppm 
0 
1 
2 
1.68 
ppm 
2 
1 
0 
To determine the ratios of each compound in the mixtures, the integrated 
chemical shift areas were compared. However, some chemical shifts corresponded to 
more than one compound (Table 5.9), so equations were constructed to calculate the 
contributions of each compound. In all equations, x corresponds to squalene, y to DOS, 
and e to epicoprostanol. Samples containing epicoprostanol compared the peaks in the 
table above to the epicoprostanol methyl peaks at 0.63 ppm and 0.92 ppm. 
Epicoprostanol has no chemical shifts in common with the acyclic compounds so no 
equations were formulated. From the data collected, only two mixtures could be 
accurately integrated due to contaminations present in the other samples interfering with 
the methyl shifts to be integrated. Therefore only the squalene + DOS and DOS + 
epicoprostanol numbers are reported here. 
For the squalene + DOS mixture, the 1.68 ppm shift corresponded only to 
squalene, while the 1.26 ppm, 1.30 ppm, and 1.62 ppm shifts were characteristic for only 
DOS (Table 5.10). The two compounds both have 1.60 ppm peaks, so the equation below 
was utilized to determine the ratios. 
1.60 ppm = 6x + 2y 
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Table 5.10. NMR integration results from the squalene + DOS mixture. Chemical shifts 
are calculated in ppm and integration values are based on peak areas. Squalene 
corresponds to x and DOS to y. 
Chemical 
shift 
1.26 
1.3.0 
1.60 
1.62 
1.68 
Integration 
value 
0.986 
1.00 
3.388 
0.886 
0.893 
Equation 
2y 
2y 
6x + 2y 
2y 
2x 
Calculated values 
y = 0.463 
y = 0.50 
x = 0.410, y = 0.463 
y = 0.443 
x = 0.446 
From these integration values, squalene was calculated as being 89% of DOS. 
Comparing 1.26 ppm and 1.30 ppm, there is a 1.4% difference in integration. The allylic 
and aliphatic methyl groups integrated similarly to one another as well. The correction 
factor here is thus DOS/squalene = 0.90, with a 1.4% possible error. 
Finally, a mixture of DOS and epicoprostanol was examined (Table 5.11). The 
two methyl groups integrated for epicoprostanol were within 3% of one another. The 
allylic methyl peaks in DOS integrated similarly to the aliphatic methyl groups, with an 
8% difference in integration values. The DOS/epicoprostanol ratio was thus calculated as 
0.87 within 11% error. 
Table 5.11. NMR integration results from the DOS + epicoprostanol mixture. Chemical 
shifts are reported in ppm and integration values determined from peak areas. 
Epicoprostanol corresponds to e and DOS corresponds to y. 
Chemical 
shift 
0.64 
0.92 
1.26 
1.30 
1.60 
1.62 
Integration 
value 
3 
2.9 
5.1 
5.3 
4.9 
5.1 
Equation 
e 
e 
2y 
2y 
2y 
2y 
Calculated values 
e = 3 
e = 2.9 
y = 2.6 
y = 2.7 
y = 2.5 
y = 2.6 
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Determination of correction factors for DOS quantitation. The data from both 
GC-FID quantitation of TMS-derivatized samples and NMR quantitation of the non-
derivatized mixtures were taken together to determine correction factors for DOS 
quantitation (Table 5.12). The NMR values were thought to provide a more accurate 
picture of the relative amounts of squalene, OS, DOS, or epicoprostanol present in the 
given mixture; however the results were not definitive. The corrected values are shown in 
Tables 5.7 and 5.8 in the Results and Discussion section. 
Table 5.12. Correction factors calculated from NMR integration and GC-FID 
quantitation of TMS-derivatized samples. These factors were applied to the 
SMY8[pRS305Gal], ABY1, and ABY2 quantitation results. 
Mixture 
DOS/Squalene 
DOS/epicoprostanol 
Before TMS-
derivatization 
0.88 
0.854 
After TMS-
derivatization 
0.86 
0.628 
NMR 
calculated 
ratio 
0.90 
0.83 
Final 
correction 
factor 
Negligible 
1.32 
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Chapter 6 
Conclusions 
Metabolic engineering has come to the forefront in biosynthesizing terpenoids, 
and the work presented here shows the incredible potential this technology has for 
increasing terpene production in a microbial host. By manipulating enzymes in the S. 
cerevisiae sterol biosynthetic pathway, terpene precursor accumulation increased, 
yielding higher levels of terpenoid products. This optimization was achieved by 
improving activity of foreign terpene synthases or by increasing carbon flux to the 
desired terpenoid precursors through over-expression of rate-limiting enzymes or deletion 
of competing enzymes in the S. cerevisiae sterol biosynthetic pathway. 
We began with an existing engineered strain that overproduces the diterpene 
precursor geranylgeranyl pyrophosphate (GGPP). Expression of two diterpene synthases 
from the Arabidopsis thaliana gibberellin biosynthetic pathway, e«/-copalyl 
pyrophosphate synthase and e/rt-kaurene synthase, led to milligram-level accumulation of 
the e«J-copalyl pyrophosphate hydrolysis products e«/-copalol, e«7-manool, and ent-13-
epimanool, as well as the tetracyclic product ew/-kaurene. Additionally, the GGPP 
hydrolysis products geranylgeraniol and geranyllinalool were isolated in high yields. This 
work demonstrated the utility of increasing substrate accumulation to improve terpene 
production in vivo. 
To further enhance yields, a novel method was developed in which a chloroplast 
processing enzyme from Arabidopsis was co-expressed in our diterpene-producing 
systems. This enzyme cleaved plastid-targeting peptides from the co-expressed diterpene 
91 
synthases, forming mature proteins that then exhibited better enzymatic activity. The 
strain containing Abies grandis abietadiene synthase showed a 1.5-fold increase in 
abietadiene production when the CPE was added, while the strain with Arabidopsis ent-
copalyl pyrophosphate synthase and en?-kaurene synthase saw a 5-to 10-fold increase in 
ewf-kaurene production when the CPE was present. 
Yeast strains with a non-functional squalene synthase accumulate farnesyl 
pyrophosphate (FPP), which readily hydrolyzes to farnesol and nerolidol. This work 
revealed that a majority of the farnesol and nerolidol production is non-enzymatic, and 
media pH controlled the product profile towards either farnesol or nerolidol. A more 
acidic pH directed FPP hydrolysis towards nerolidol production, whereas farnesol was 
formed as the major product under a more neutral pH. 
Finally, over-expression of a soluble form of the rate-limiting enzyme HMG-CoA 
reductase in a strain lacking lanosterol synthase activity accumulated large amounts of 
the triterpene substrates oxidosqualene and dioxidosqualene, with twenty times more 
material isolated than that observed in the parent strain. Over-expression of squalene 
epoxidase facilitates oxidation of oxidosqualene to dioxidosqualene, with 80 times more 
dioxidosqualene than oxidosqualene accumulating. 
This thesis demonstrates several novel approaches to enhancing terpenoid 
production in microbial hosts. As terpene precursor accumulation was dramatically 
increased in sesquiterpene, diterpene, and triterpene systems, these strains can be utilized 
to express terpene synthases and aid in enzyme characterization. Metabolic engineering 
of microbes has yet to reach optimal levels, and more modifications can still be 
undertaken to further increase terpenoid production. 
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Chapter 7 
Experimental Procedures 
Materials. Media ingredients were purchased from United States Biological 
(Swampscott, MA). Hemin chloride (heme), ergosterol, Tween 80, 
bis(trimethylsilyl)trifluoroacetamide (BSTFA), and Triton X-100 were from Sigma-
Aldrich (St. Louis, MO). HP Diaion-20 resin was obtained from Supelco (Bellefonte, 
PA). Solvents, silica gel 60, and TLC plates were obtained from EMD Chemicals, Inc. 
(Gibbstown, NJ). Restriction enzymes, DNA ladders, and Quick Ligation Kit were 
purchased from New England Biolabs (Beverly, MA), and the High Purity Plasmid 
Miniprep System was from Marligen Biosciences, Inc. (Ijamsville, MD). A Qiagen Gel 
Extraction Kit was used to extract DNA from agarose gel (Valencia, CA). PCR 
amplification was performed with Triple Master polymerase from Eppendorf (Westbury, 
NY) and dNTPs from Takara (Fisher Scientific, Pittsburg, PA). The TOPO-TA Cloning 
Kit for Sequencing and One-Shot chemically competent cells were purchased from 
Invitrogen (Carlsbad, CA) and used according to the manufacturer's instructions. 
Gas chromatography-flame ionization detection (GC-FID). GC-FID analysis 
was done with an Agilent 6890 GC-FID instrument using a Restek Rtx-35 column (30 m 
x 0.25 mm x 0.1 urn). Samples (1 [iL) were injected into the inlet heated to 280 °C with a 
40:1 split ratio. The flame ionization detector temperature was 290 °C, with air flow at 
264 mL/min, hydrogen flow at 39 mL/min, and helium makeup gas flow at 37 mL/min. 
The column was set to constant pressure, dependent on the method used. 
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For sesquiterpene analysis, a ramping temperature program was used as follows: 
50 °C held for 1 min and ramping 15 °C/min until 200 °C was reached. A ramp of 40 
°C/min to a final temperature of 280 °C was used, holding at 280 °C for 15 min. The 
column was held at a constant pressure of 15.13 psi. 
Diterpene extracts were analyzed using a similar ramping program. The oven 
started at 100 °C for 1 min, followed by a 15 °C/min ramp to 200 °C. This temperature 
was held 5 min before ramping to 280 °C at a rate of 40 °C/min. The final temperature 
was held 22 min, giving a total run time of 36.67 min. The column and inlet were held at 
a constant pressure of 6.53 psi. 
For triterpene analysis, samples were run on an isothermic program of 260 °C for 
32 min, with a constant pressure of 25.73 psi. 
Gas chromatography-mass spectrometry (GC-MS). GC-MS analysis was 
performed on an Agilent 6890N GC instrument interfaced to an Agilent 5973N MSD 
system with a Restek Rtx-35ms column (30 m x 0.25 mm x 0.1 \xm). Aliquots of 1 - 5 
uL were injected at a 40:1 split ratio into an inlet at 280 °C. The MSD was heated to 280 
°C and set to analyze after a 3 min solvent delay. 
For sesquiterpene analysis, chromatography was run with a ramping temperature 
program, starting at 50 °C for one min and ramping 15 °C/min until it reached 200 °C. 
This temperature was held for 5 min before increasing 40 °C/min to a final temperature 
of 280 °C. This final temperature was held for 5 min. The column had a constant pressure 
of 7.79 psi, with a helium flow of 0.9 mL/min. The MSD was set to analyze 50-500 amu 
after a 3 min solvent delay. 
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Analysis of diterpene products utilized a similar ramping program, with the oven 
starting at 100 °C for 1 min. A 15 °C/min ramp to 200 °C followed, with this temperature 
held for 5 min. Finally the temperature was increased 40 °C/min to a final temperature of 
280 °C, which was held for 15 min. A constant flow of helium travelled through the 
column at 1 mL/min, with a column pressure of 7.58 psi. The MSD analyzed 50 - 500 
amu after a 3 min solvent delay. 
For triterpene analysis, chromatography was run on an isothermic program of 260 
°C for 32 min. The column was set to a constant flow of 1 mL/min with a pressure of 
19.22 psi. The MSD was set to analyze 50-650 amu after a 3 min solvent delay. 
Nuclear magnetic resonance (NMR). 'H NMR spectra were acquired at 25 °C in 
dilute CDC13 solution on Varian Inova 600 or 800 MHz or Bruker 500 MHz 
spectrometers. Spectra were referenced to tetramethylsilane at 0 ppm. Deuterated 
chloroform was filtered over activated basic alumina prior to use and contained a 5:1 
mixture of CDCI3 and CDCI3 with 0.05% TMS. 
UV-Visible spectroscopy. A Shimadzu UV-visible spectrophotometer UV-1601 
was used for all measurements, analyzing at 600 nm wavelength. Disposable cuvettes (10 
mM UV-grade) were purchased from VWR International, Inc. (Westchester, PA). 
Incubations. All microbial plate cultures were grown in Fisher Scientific Isotemp 
incubators, set at either 30 °C (for S. cerevisiae) or 37 °C (for E. coli). Liquid cultures 
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were grown in either a New Brunswick Series 25 Incubator Shaker or a New Brunswick 
C24 Incubator Shaker, both set at 200 rpm with temperature set at either 30 °C or 37 °C. 
Centrifugation. Centrifugation of Eppendorf tubes (1.5 mL) were performed 
using either an Eppendorf Centrifuge 5415D or 581 OR. Larger tubes (15-mL, 50-mL 
Falcon tubes or 250-mL centrifuge bottles) were centrifuged using an Eppendorf 
Centrifuge 5810 at variable speeds and temperatures. 
E. coli and yeast strains. For plasmid work, the E. coli strain DH5a (F~ endAl 
hsdRl7(rk~, mk+) supE44 thi-l X recKX gyrA.96 relAl A(/acZYA-
argF)ui69(m80/acZAM15))163 was used. Five yeast strains were utilized for metabolic 
engineering work. For sesquiterpene production, three different strains were analyzed. 
PMY1 (MATaPGALl-trHMGl::LEU2 erg9::HIS3 heml::TRPl ura3-52 trpl-A63 his3-
A200 ade2 GAL+) is a squalene synthase deletion mutant with a truncated HMG-CoA 
reductase (trHMGl) over-expressed. Two PMY1 derivatives PMY2 (MATa 
dppl::KanMXpGALl-trHMGl::LEU2 erg9::HIS3 heml::TRPl ura3-52 trpl-A63 his3-
A200 ade2 GAL+) and BEJY14 (MATa lppl::KanMXpGALl-trHMGl::LEU2 erg9::HIS3 
heml::TRPl ura3-52 trpl-A63 his3-A200 ade2 GAL+)m contain DPP1 and LPP1 
deletions, respectively. These three strains all accumulate the C-15 linear precursor 
farnesyl pyrophosphate. 
The EHY18 yeast strain (MATapGALl-BTSl:.hispGALl-trHMGl ::LEU2 ura3-
52 trpl-A63 leu2-3,112 his3-A200 ade2 Gal+)35'1U was used for diterpene experiments 
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and contained trHMGl and GGPP synthase over-expressed, accumulating the C-20 
intermediate geranylgeranyl pyrophosphate. 
SMY8 (MAT* erg7::HIS3 heml::TRPl ura3-52 trpl-A63 leu2-3,112 his3-A200 
ade2 GAL+)120 is a lanosterol synthase deletion mutant that accumulates the C-30 
triterpene precursors oxidosqualene and dioxidosqualene. This strain was engineered 
further to increase accumulation of these intermediates. 
Bacterial media. E. coli cultures were grown in Luria-Bertani broth (LB).163 This 
was prepared by dissolving 10 g of LB powder, containing 5 g tryptone, 2.5 g yeast 
extract, and 2.5 g NaCl, in 500 mL mqH20. The LB medium was sterilized by 
autoclaving at 250 °C for 35 min. Solid LB media was prepared as described above 
except with the addition of 7.5 g agar/500 mL prior to sterilization. Selective plates were 
supplemented with the antibiotic ampicillin to a final concentration of 100 ug/mL. 
For E. coli transformations, cells were incubated with SOC media prior to plating. 
SOC media contained 2.5 g yeast extract, 10 g tryptone, 1.8 g glucose, 10 mM NaCl 
(292 mg), 2.5 mM KC1 (93 mg), 10 mM MgCl2 (1.017 g anhydrous, 2.03 g hexahydrate), 
and 20 mM MgSC<4 (2.465 g), all dissolved in 500 mL mqH20 and autoclaved as 
described above. 
Preparation of competent cells also required TB media, prepared by dissolving 
1.51 g PIPES, 9.31 g KC1, and 0.832 g CaCl2 in 500 mL mqH20. The pH was adjusted to 
6.7 with 5 M NaOH. Once everything was dissolved, 5.44 g MnCl2 x 4H20 was added. 
The mixture was filter-sterilized and stored at 4 °C. 
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Yeast media. Yeast media were sterilized by autoclaving at 250 °C for 25 or 35 
min. Optimal growth required equal volumes of both a nitrogen source and a carbon 
source. The nitrogen sources used were either YP or synthetic complete. YP was 
prepared as a 2 x solution with 5 g yeast extract and 10 g peptone dissolved in 500 mL 
mqH20. Synthetic complete media was prepared with 1.7 g yeast nitrogen base, 5 g 
ammonium sulfate, and 2 g of amino acid mix dissolved in 500 mL mqtkO, with the 
final pH adjusted to ~6 with solid NaOH pellets. The amino acid mix contained 10 g 
leucine and 2 g of the following: alanine, arginine, asparagine, aspartate, cysteine, 
glutamine, glutamate, glycine, histidine, isoleucine, lysine, methionine, phenylalanine, 
proline, serine, threonine, tryptophan, tyrosine, valine, adenine, and uracil. Selective 
media, such as SC-Ura, used an amino acid mix deficient in the specified component. 
Sugar solutions of dextrose or galactose were used as carbon sources. Dextrose 
was prepared as a 2 x solution containing 20 g dextrose dissolved in 500 mL mqHaO. 
Galactose, used to induce enzyme expression under a galactose-inducible promoter, was 
prepared as a 2 x solution containing 20 g galactose dissolved in 500 mL mqfkO. 
For solid yeast media, 7.5 g agar/500 mL was added to the carbon sources prior to 
sterilization. Plates contained 15 mL each of a carbon source and a nitrogen source. 
For yeast strains with nonfunctional sterol biosynthetic pathways, ergosterol was 
supplemented into the media as a 100 x solution containing 20 ug/mL in EtOH and the 
detergent Tween 80. These strains also contain a deletion in the heme biosynthetic 
pathway to mimic anaerobic growth conditions, as yeast will not import sterols under 
aerobic conditions. This required supplemental hemin as a 100 x solution (65 mg hemin 
chloride in 25 mL EtOH and 25 mL mqH20 with l m L I M NaOH). 
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Preparation of DH5a competent cells. For all bacterial work, homemade DH5a 
competent cells163 were used. The glycerol stock of DH5a was used to inoculate 5 mL 
LB and incubated overnight at 37 °C with shaking. A 500-mL portion of freshly-prepared 
SOC media was inoculated with the 5-mL DH5ot culture, incubated at room temperature 
6 - 8 h and then transferred to a 4 °C refrigerator overnight. The flask was then put back 
into the room temperature incubator until the ODeoo had reached approximately 0.6. At 
this point the cultures were transferred to chilled 250-mL centrifuge bottles and 
centrifuged 15 min at 3000 rpm, 4 °C. 
The supernatant was removed and each set of cells was resuspended in 80 mL ice-
cold, freshly-prepared TB media and incubated on ice 10 min. The mixtures were then 
centrifuged 15 min at 3000 rpm, 4 °C and the supernatant was removed. The cells were 
resuspended in 10 mL TB per bottle and resuspended with gentle swirling. DMSO was 
added to a final concentration of 7% (0.75 mL DMSO per 10 mL TB) and the mixture 
was incubated on ice 10 min. The chilled solutions were transferred to chilled 1.5-mL 
Eppendorf tubes in 50 uL aliquots. The tubes of cells were frozen by immersion in liquid 
nitrogen and immediately transferred to a -80 °C freezer for storage. 
DNA purification. For mini-prep DNA purification E. coli cultures were 
inoculated in 12-well plates containing 2-mL LB + Amp and incubated overnight at 37 
°C. The well plates were centrifuged for 10 min at 3000 rpm, 4 °C and the supernatants 
were discarded. The cell pellets were resuspended in 100 uL chilled PI buffer containing 
Rnase A (50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 20 mg/mL Rnase A). To lyse the 
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cells, 100 uL P2 buffer (200 mM NaOH, 1% SDS (w/v))was added and the mixture was 
incubated at room temperature up to 5 min, followed immediately by addition of an equal 
volume of chilled P3 buffer (3.1 M potassium acetate, pH 5.5). These mixtures incubated 
at 4 °C for at least 30 min and then centrifuged at 3000 rpm for 10 min. The supernatants 
were transferred to 1.5-mL Eppendorf tubes and DNA pellets were precipitated with two 
volumes EtOH and 0.1 M NaCl (600 uL EtOH and 6 uL 5 M NaCl). The tubes left at -20 
°C for at least 30 min and centrifuged 20 min at 12,000 rpm, 4 °C. The supernatants were 
removed by decanting and the DNA pellets were left at 37 °C to allow the remaining 
EtOH to evaporate. The dried pellets were resuspended in 30 uL Tris pH 8.0 buffer (10 
mM Tris-HCl pH 8.0). 
For large-scale DNA purification bacterial cultures of either 50 or 100 mL were 
grown overnight at 37 °C and centrifuged for 20 min at 3500 rpm. The supernatants were 
removed by decantation and pipette, and the cell pellets were resuspended in 2 mL 
chilled PI buffer with Rnase A. This was followed by the addition of 2 mL P2 buffer and 
incubation on the bench for 5 min. An equal volume of chilled P3 buffer was added and 
the mixtures were incubated at 4 °C at least 30 min. The tubes were centrifuged for 10 
min at 3500 rpm and the supernatants were filtered over Mira Cloth into a clean 50-mL 
Falcon tube. To this was added 0.7 volumes isopropyl alcohol (IPA), and the mixture was 
aliquoted into 1.5-mL Eppendorf tubes and incubated at -20 °C for at least 30 min. The 
tubes were centrifuged for 20 min at 12000 rpm and 4 °C and the supernatants were 
discarded. The DNA pellets were placed in a 37 °C incubator to remove the residual IPA. 
To one tube was added 400 uL mqHbO and the DNA pellet was resuspended by pipetting 
the mixture up and down several times. This mixture was added to the second tube 
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containing a DNA pellet, and this procedure was repeated until all DNA pellets were in 
one tube containing 400 uL water. The tube was incubated at 37 °C to ensure all DNA 
had dissolved and then centrifuged in a microfuge for 1 min. The supernatant was 
transferred to a clean Eppi tube and two volumes EtOH and 0.1 M NaCl were added (600 
uL EtOH and 6 uL 5 M NaCl). This was mixed by inverting the tube several times and 
then incubated at -20 °C for at least 30 min. Following centrifugation (20 min at 12,000 
rpm and 4 °C), the supernatant was discarded and the DNA pellet was dried at 37 °C. The 
pellet was ultimately resuspended in 50 uL Tris pH 8.0 buffer. 
Alternatively a Marligen High Purity Plasmid Miniprep System was used 
(Marligen Bioscience, Inc., Ijamsville, MD). The LB + Amp cultures were harvested by 
centrifugation, as described above. The manufacturer's protocol was followed, except 2 
mL each PI + Rnase A, P2 and P3 were used instead of 400 |^L. 
DNA sequencing was performed by Lone Star Labs, Inc. (Houston, TX) or by 
SeqWright DNA Technology Services (Houston, TX). 
Polymerase chain reaction (PCR). Oligonucleotides for PCR and sequencing 
were synthesized by Sigma-Genosys (Houston, TX) or Integrated DNA Technologies 
(Coralville, IA). Upon arrival, the DNA pellets were centrifuged and dissolved in mqH20 
to a stock concentration of 100 pmol/uL. For PCR, the stock solutions were diluted 
further to 20 pmol/uL. All were stored at -20 °C. 
PCR amplification was carried out on a Mastercycler Gradient system 
(Eppendorf, Hamburg, Germany). A CAPS program was used, with the following 
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temperature program: 95 °C for 1 min, 65 °C for 30 s, 72 °C for 3 min, and a 5 min 
extension at 72 °C, all repeated 36 times. 
PCR amplification typically was performed using either plasmid DNA or a cDNA 
library as template. All reactions contained 0.5 uL template, 20 pmol of each primer, 4 
uL dNTPs, 5 uL of the required buffer, and 0.2 — 1 |j.L polymerase. Reactions were 
brought up to 50 uL with sterile mqHbO. 
For colony PCR, the reactions contained 20 pmol of each primer, 4 uL dNTPs, 5 
uL PC2 buffer, and 0.5 uL Taq polymerase (a generous gift from Prof. Bonnie Bartel) 
and were brought to 50 uL total volume with sterile mqE^O. Yeast or E. coli colonies 
were then used to inoculate each reaction. 
DNA restriction digestions. All restriction digestions were done according to the 
New England BioLabs instructions. To map mini-prep DNA, 1 uL plasmid DNA was 
digested in a 10 uL reaction, containing 1 uL 10 x buffer and 0.2 - 0.3 uL enzyme and 
0.1 uL 100 x BSA (if needed) and the remaining volume was rnqF^O. For large-scale 
DNA preparation 1 uL of plasmid was digested in a mixture containing 2 uL 10 x buffer, 
0.5 uL enzyme, 0.2 uL 100 x BSA (if needed), and mqH20 up to 20 uL total volume. 
For cloning and subcloning, between 5 and 20 uL of plasmid DNA was digested 
in 50 - 100 uL reactions. These included 10 x buffer, 0.5 - 1 uL of each enzyme, 100 x 
BSA (as needed), and mqEkO up to the final volume. 
For integrative plasmids, linearization was performed prior to yeast 
transformations. Typically 25 - 50 uL plasmid DNA was digested in 200 \\L total 
reaction volume. 
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Analytical gel electrophoresis. For analytical purposes, a 1% agarose gel was 
prepared by dissolving 5 g agarose in 500 mL TAE buffer (50 x TAE stock contained 
242 g Tris base, 57.1 mL glacial acetic acid, and 100 mL 0.5 M EDTA dissolved in 1 L 
mqEbO) and adding ethidium bromide to the melted agarose (5 uL/100 mL agarose gel). 
To the DNA samples was added a 10 x loading buffer (20% Ficoll 400, 0.1 M EDTA, 
0.25% bromophenol blue, and 0.25% xylene cyanol). Samples were loaded onto the gel 
and analyzed against the DNA ladder marker TdisiE II (2 uL, New England BioLabs). 
Gel purification of DNA. A 1% agarose gel was prepared by mixing 5 g agarose 
in 500 mL of GTAE buffer (same as TAE buffer with addition of guanosine 2.38 g/10 L 
buffer) and microwaving until a homogeneous mixture was obtained. Ethidium bromide 
(5 uX/100 mL) was added and the gel was poured into the mold and allowed to set. The 
DNA samples were analyzed against the DNA ladder marker XBstE II (5 uL). The desired 
bands were excised from the gel with a razor blade and purified using the QIAquick Gel 
Extraction Kit (Qiagen), following the manufacturer's instructions. 
Ligations. DNA ligations were performed using a Quick Ligation Kit (New 
England BioLabs, Beverly, MA) following the manufacturer's instructions. Each reaction 
contained 50 ng vector and a 3- to 5-fold molar excess of insert, up to 9 uL total volume. 
A 10-uL aliquot of 2 x Quick Ligation Buffer and 1 uL Quick Ligase was used for each 
reaction, for a total volume of 20 uL. Incubations were done at room temperature for 5 
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min to 1 h, with 1 uL removed prior to addition of ligase and 1 uL removed after 
incubation to run on an analytical gel. 
E. coli transformations. A tube of DH5a competent cells was removed from the 
-80 °C freezer and allowed to thaw on ice 5 min. Once thawed, 5 uL of the ligation 
mixture was added to the cells and incubated on ice for 30 min. Following a 30-s heat 
shock at 42 °C, 500 uL SOC media was added and the mixture was incubated with 
shaking for 30 min to 1 h. Two aliquots of the transformation, typically 50 uL and 200 
uL, were plated on LB plates containing antibiotic and incubated at 37 °C overnight. 
Yeast transformations. Yeast transformations were carried out using the lithium 
acetate method.119 Cultures were centrifuged at 3000 rpm for 3 min and the supernatant 
was discarded. The cell pellet was washed twice with 10 mL sterile rnqt^O and 
centrifuged for 3 min at 3000 rpm after each wash. The pellet was then suspended in 100 
uL of sterile deionized water and vortexed. To the yeast suspension was added 10 uL 
plasmid DNA and 50 uL single-stranded DNA, which had been denatured in boiling 
water for 5 min. After this mixture was vortexed, 2 mL of yeast transformation buffer 
(40% polyethylene glycol (PEG), 0.1 M lithium acetate, 10 mM Tris pH 7.5, 1 mM 
EDTA, and 0.1 M dithiothreitol)119 was added and the solution was vortexed again to 
mix. This mixture was incubated at room temperature. 
After incubation for 6-18 h, 15 mL sterile mqHbO was added to the solution, re-
suspending the cell pellet, and centrifuged at 3000 rpm for 4 min and the supernatant was 
decanted. The cell pellet was then washed twice with 10 mL sterile mqtfeO and 
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centrifuged for 4 min at 3000 rpm to remove any remaining PEG. The cell pellet was 
resuspended in 500 uL of sterile deionized water and 250 |xL was plated on selective 
media. 
For integrative plasmids, in pRS305Gal120 or pRS305biGal, the plasmid DNA 
was first linearized with BstE II or BsrG I and then used for transformation. Digested 
plasmids and 100 uL denatured ssDNA were used to transform yeast, with the remainder 
of the procedure following that described above. 
Saponification and extraction. Dextrose cultures (10 mL) were inoculated from 
single yeast colonies and grown to saturation. From these cultures, 100-mL galactose 
cultures were inoculated (either 1-mL or 10-mL inocula) and grown to log-phase or 
saturation, as determined by checking OD6oo- For large-scale cultures, a 1% or 10% 
inocula was used to start at least 1 L in inducing medium. Cells were harvested by 
centrifugation and the cell pellets were then saponified in a mixture of 10% KOH in 80% 
ethanol. To prevent oxidation, 2 mg of the antioxidant butylated hydroxytoluene (BHT, 
Sigma) was added per 1 g cell pellet before saponification. The mixture was heated in a 
70 °C water bath for 2 h and then cooled to room temperature. The non-saponifiable 
lipids (NSL) were extracted with three aliquots of hexane. The combined extracts were 
washed with two portions of water and one aliquot of brine before the solvent was 
evaporated in vacuo. The residue was transferred to a small vial with hexane and the 
remaining solvent was evaporated under a nitrogen gas stream. 
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Isolation of terpenes from media with hydrophobic resin. Once saturated, 
yeast cultures were transferred to 250-mL flasks containing methanol-activated 
hydrophobic resin (Diaion-20, Supelco) and were incubated at 30 °C with shaking 
overnight. Cultures were then filtered through Kontes columns and the cells and media 
were discarded. The resin remaining in the column was washed with 3 volumes of 
ethanol and the combined ethanol was then partitioned between one-half volume of water 
and three one-half volumes of pentane (for sesquiterpenes) or hexanes (for diterpenes and 
triterpenes). The pentane or hexane extracts were concentrated by rotary evaporation and 
transferred to small vials with pentane, hexane, or methylene chloride. Ten percent of 
each extract was used for GC-MS and GC-FID analysis. 
Quantitation of terpene products. To quantitate the terpene products, the 
internal standard longifolene (for sesquiterpenes) or epicoprostanol (for diterpenes and 
triterpenes) was added for comparison. To quantitate NSL, the internal standard was 
added prior to saponification. The internal standard was added to the ethanolic fractions 
to quantitate resin extracts, prior to extraction with hexane or pentane. Samples were 
analyzed by GC-MS and GC-FID, and the peak areas corresponding to terpene products 
were compared to those of the internal standard. 
Preparation of TMS-ethers for triterpene analysis. For analysis of triterpene 
products, it was sometimes necessary to convert the alcohols to TMS-ethers for more 
accurate quantitation. This was done by transferring a small amount of the sample in a 
GC vial containing a 300-uL insert and evaporating the solvent under a nitrogen stream. 
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The samples were then dissolved in a 1:1 mixture of pyridine (dried over KOH) and 
bis(trimethylsilyl)trifluoroacetamide (BSTFA, Sigma-Aldrich). Samples were mixed by 
inverting several times, and the vials were left at 37 °C overnight to ensure complete 
conversion to the TMS-ether. 
Column chromatography. To purify terpene products, all column 
chromatography utilized silica gel 60 (250 - 400 mesh). For sesquiterpenes, gradient 
systems of pentane/ether were used for separation, while mixtures of hexane/ether were 
used for diterpenes and triterpenes. Samples were dissolved in a small amount of the 
same solvent system being used for purification and added to the pre-washed column. 
Fractions were monitored by TLC. 
107 
References 
(1) Rohmer, M.; Seemann, M.; Horbach, S.; Bringer-Meyer, S.; Sahm, H. J. 
Am. Chem. Soc. 1996,118, 2564-2566. 
(2) Schwender, J.; Seemann, M.; Lichtenthaler, H. K.; Rohmer, M. Biochem 
J. 1996, 316, 73-80. 
(3) Lange, B. M.; Wildung, M. R.; McCaskill, D.; Croteau, R. Proc. Natl. 
Acad. Sci. USA 1998, 95, 2100-2104. 
(4) Servouse, M.; Mons, N.; Baillargeat, J.-L.; Karst, F. Biochem. Biophys. 
Res. Commun. 1984,123, 424-430. 
(5) Hiser, L.; Basso, M. E.; Rine, J. J. Biol. Chem. 1994, 269, 31383-31389. 
(6) Middleton, B.; Tubbs, P. K. Biochem. J. 1972,126, 27-34. 
(7) Servouse, M.; Karst, F. Biochem. J. 1986, 240, 541-547. 
(8) Schroepfer, G. J. Annu. Rev. Biochem. 1981, 50, 585-621. 
(9) Dietchy, J. M.; Brown, M. S. J. Lipid Res. 1974,15, 508-514. 
(10) Basson, M. E.; Thorsness, M.; Rine, J. Proc. Natl. Acad. Sci. USA 1986, 
83, 5563-5567. 
(11) Liscum, L.; Finer-Moore, J.; Stroud, R. M; Luskey, K. L.; Brown, M. S.; 
Goldstein, J. L. J. Biol. Chem. 1985, 260, 522-530. 
(12) Goldstein, J. L.; Brown, M. S. Nature 1990, 343, 425-430. 
(13) Dimster-Denk, D.; Thorsness, M. K.; Rine, J. Mol. Biol. Cell 1994, 5, 655-
665. 
(14) Hampton, R. Y.; Rine, J. J. Cell Biol. 1994,125, 299-312. 
108 
(15) Hampton, R. Y.; Bhakta, H. Proc. Natl. Acad. Sci. USA 1997, 94, 12944-
12948. 
(16) Gardner, R. G.; Hampton, R. Y. J. Biol. Chem. 1999,274, 31671-31678. 
(17) Wright, R.; Basson, M.; D'Ari, L.; Rine, J. J. Cell. Biol. 1988,107,101-
114. 
(18) Polakowski, T.; Stahl, U.; Lang, C. Appl. Microbiol. Biotechnol. 1998, 49, 
66-71. 
(19) Donald, K. A. G.; Hampton, R. Y.; Fritz, I. B. Appl. Environ. Microbiol. 
1997, 63, 3341-3344. 
(20) Karst, F.; Lacroute, F. Mol. Gen. Genetics 1977,154, 269-277. 
(21) Tsay, Y. H.; Robinson, G. W. Mol. Cell. Biol. 1991, / / , 620-631. 
(22) Toth, M. J.; Huwyler, L. J. Biol. Chem. 1996, 271, 7895-7898. 
(23) Chambon, C ; Ladeveze, V.; Servouse, M.; Blanchard, L.; Javelot, C ; 
Vladescu, B.; Karst, F. Lipids 1991, 26, 633-636. 
(24) Anderson, M. S.; Muehlbacher, M.; Street, I. P.; Proffitt, J.; Poulter, C. D. 
J. Biol. Chem. 1989, 264, 19169-19175. 
(25) Ashby, M. N.; Edwards, P. A. J. Biol. Chem. 1990, 265, 13157-13164. 
(26) Davis, E. M.; Croteau, R. Top. Curr. Chem. 2000, 209, 53-95. 
(27) Anderson, M. S.; Yarger, J. G.; Burck, C. L.; Poulter, C. D. J. Biol. Chem. 
1989,264, 19176-19184. 
(28) Chambon, C.; Ladeveze, V.; Oulmouden, A.; Servouse, M.; Karst, F. 
Curr. Genet. 1990,18, 41-46. 
(29) Blanchard, L.; Karst, F. Gene 1993,125, 185-189. 
109 
(30) Fernandez, S. M. S.; Kellogg, B. A.; Poulter, C. D. Biochemistry 2000, 39, 
15316-15321. 
(31) Karst, F.; Plochocka, D.; Meyer, S.; Szkopinska, A. Cell Biol. Int. 2004, 
28,193-197. 
(32) Szkopinska, A.; Swiezewska, E.; Karst, F. Biochem. Biophys. Res. 
Commun. 2000, 267, A13-A11. 
(33) Lorenz, R. T.; Rodriguez, R. J.; Lewis, T. A.; Parks, L. W. J. Bacteriol. 
1986,167, 981-985. 
(34) Jiang, Y.; Proteau, P.; Poulter, D.; Ferro-Novick, S. J. Biol. Chem. 1995, 
270,21793-21799. 
(35) Hart, E. A.; Ph. D. Thesis, Rice University, 2001. 
(36) Clarke, S. Annu. Rev. Biochem. 1992, 61, 355-386. 
(37) Moores, S. L.; Schaber, M. D.; Mosser, S. D.; Rands, E.; O'Hara, M. B.; 
Garsky, V. M.; Marshall, M. S.; Pompliano, D. L.; Gibbs, J. B. J. Biol. Chem. 1991, 266, 
14603-14610. 
(38) Sasiak, K.; Rilling, H. C. Arch. Biochem. Biophys. 1988, 260, 622-627. 
(39) Jennings, S. M.; Tsay, Y. H.; Fisch, T. M.; Robinson, G. W. Proc. Natl. 
Acad. Sci. USA 1991, 88, 6038-6042. 
(40) Rilling, H. C ; Poulter, C. D.; Epstein, W. W.; Larsen, B. J. Am. Chem. 
Soc. 1971, 93, 1783-1785. 
(41) Grabowska, D.; Karst, F.; Szkopinska, A. FEBSLett. 1998, 434,406-408. 
(42) Song, L. Anal. Biochem. 1993, 317, 180-185. 
(43) Tchen, T. T.; Bloch, K. J. Am. Chem. Soc. 1955, 77, 6085-6086. 
110 
(44) Jandrositz, A.; Turnowsky, F.; Hogenauer, G. Gene 1991,107, 155-160. 
(45) M'Baya, B.; Karst, F. Biochem. Biophys. Res. Commun. 1987,147, 556-
564. 
(46) Tchen, T. T.; Bloch, K. J. Biol. Chem. 1957,226, 931-939. 
(47) Klein, H. P. J. Bacteriol. 1955, 69, 620-627. 
(48) Leber, R.; Zenz, R.; Schrottner, K.; Fuchsbichler, S.; Puhringer, B.; 
Turnowsky, F. Eur. J. Biochem. 2001, 268, 914-924. 
(49) M'Baya, B.; Fegueur, M.; Servouse, M.; Karst, F. Lipids 1989,24, 1020-
1023. 
(50) Bai, M.; Xiao, X. Y.; Prestwich, G. D. Biochem. Biophys. Res. Commun. 
1992,185, 323-329. 
(51) Veen, M.; Stahl, U.; Lang, C. FEMS Yeast Res. 2003, 4, 87-95. 
(52) Corey, E. J.; Matsuda, S. P. T.; Bartel, B. Proc. Natl. Acad. Sci. USA 
1994, 91, 2211-2215. 
(53) Corey, E. J.; Gross, S. K. J. Am. Chem. Soc. 1967, 89, 4561-4562. 
(54) Boutaud, O.; Dolis, D.; Schuber, F. Biochem. Biophys. Res. Commun. 
1992,188, 898-904. 
(55) Gardner, R. G.; Shan, H.; Matsuda, S. P. T.; Hampton, R. Y. J. Biol. 
Chem. 2001,276, 8681-8694. 
(56) Kalb, V. F.; Woods, C. W.; Turi, T. G.; Dey, C. R.; Sutter, T. R.; Loper, J. 
C. DNA Cell Biol. 1987, 6, 529-537. 
(57) Marcireau, C ; Guyonnet, D.; Karst, F. Curr. Genet. 1992, 22, 267-272. 
(58) Lorenz, R. T.; Parks, L. W. DNA Cell Biol. 1992,11, 685-692. 
I l l 
(59) Bard, M.; Brunei-, D. A.; Pierson, C. A.; Lees, N. D.; Biermann, B.; Frye, 
L.; Koegel, C ; Barbuch, R. Proc. Natl. Acad. Sci. USA 1996, 93, 186-190. 
(60) Gachotte, D.; Barbuch, R.; Gaylor, J.; Nickel, E.; Bard, M. Proc. Natl. 
Acad. Sci. USA 1998, 95,13794-13799. 
(61) Gachotte, D.; Sen, S. E.; Eckstein, J.; Barbuch, R.; Krieger, M.; Ray, B. 
D.; Bard, M. Proc. Natl. Acad. Sci. USA 1999, 96, 12655-12660. 
(62) Gachotte, D.; Eckstein, J.; Barbuch, R.; Hughes, T.; Roberts, C ; Bard, M. 
J. Lipid Res. 2001, 42, 150-154. 
(63) Gaber, R. F.; Copple, D. M.; Kennedy, B. K.; Vidal, M.; Bard, M. Mol. 
Cell. Biol. 1989, 9, 3447-3456. 
(64) Arthington, B. A.; Hoskins, J.; Skatrud, P. L.; Bard, M. Gene 1991,107, 
173-174. 
(65) Ashman, W. H.; Barbuch, R. J.; Ulbright, C. E.; Jarrett, H. W.; Bard, M. 
Lipids 1991, 26, 628-632. 
(66) Arthington, B. A.; Bennett, L. G.; Skatrud, P. L.; Guynn, C. J.; Barbuch, 
R. J.; Ulbright, C. E.; Bard, M. Gene 1991,102, 39-44. 
(67) Skaggs, B. A.; Alexander, J. F.; Pierson, C. A.; Schweitzer, K. S.; Chun, 
K. T.; Koegel, C ; Barbuch, R.; Bard, M. Gene 1996,169, 105-109. 
(68) Zweytick, D.; Hrastnik, C ; Kohlwein, S. D.; Daum, G. FEBSLett. 2000, 
470, 83-87. 
(69) Todd, R. B.; Andrianopolous, A. Fungal Genet. Biol. 1997, 21, 388-405. 
(70) Crowley, J. H.; Leak, F. W.; Jr.; Shianna, K. V.; Tove, S.; Parks, L. W. J. 
Bacteriol. 1998, 750,4177-4183. 
112 
(71) Lewis, T. L.; Keesler, G. A.; Fenner, G. P.; Parks, L. W. Yeast 1988, 4, 
93-106. 
(72) Leak, F. W.; Tove, S.; Parks, L. W. DNA Cell Biol. 1999,18, 133-139. 
(73) Corey, E. J.; Matsuda, S. P. T. J. Am. Chem. Soc. 1991,113, 8172-8174. 
(74) Toke, D. A.; Bennett, W. L.; Dillon, D. A.; Wu, W.; Chen, X.; Ostrander, 
D. B.; Oshiro, J.; Cremesti, A.; Voelker, D. R.; Fischl, A. S.; Carman, G. M. J. Biol. 
Chem. 1998, 273, 3278-3284. 
(75) Toke, D. A.; Bennett, W. L.; Oshiro, J.; Wu, W.; Voelker, D. R.; Carman, 
G. M. J. Biol. Chem. 1998, 273, 14331-14338. 
(76) Faulkner, A.; Chen, X.; Rush, J.; Horazdovsky, B.; Waechter, C. J.; 
Carman, G. M.; Sternweis, P. C. J. Biol. Chem. 1999, 274, 14831-14837. 
(77) Song, L. Appl. Biochem. Biotech. 2006,128, 149-157. 
(78) Fray, R. G.; Wallace, A.; Fraser, P. D.; Valero, D.; Hedden, P.; Bramley, 
P. M.; Grierson, D. Plant J. 1995, 8, 693-701. 
(79) Besumbes, O.; Sauret-Gueto, S.; Phillips, M. A.; Imperial, S.; Rodriguez-
Concepcion, M.; Boronat, A. Biotechnol. Bioeng. 2004, 88, 168-175. 
(80) Oswald, M.; Fischer, M.; Dirninger, N.; Karst, F. FEMS Yeast Res. 2007, 
7,413-421. 
(81) Reiling, K. K.; Yoshikuni, Y.; Martin, V. J. J.; Newman, J. D.; Bohlmann, 
J.; Keasling, J. D. Biotechnol. Bioeng. 2004, 87, 199-212. 
(82) Jackson, B. E.; Hart-Wells, E. A.; Matsuda, S. P. T. Org. Lett. 2003, 5, 
1629-1632. 
113 
(83) Chang, M. C. Y.; Eachus, R. A.; Trieu, W.; Ro, D.-K.; Keasling, J. D. 
Nature Chem. Biol. 2007, 3, 274-277. 
(84) Takahashi, S.; Yeo, Y.; Greenhagen, B. T.; McMullin, T.; Song, L.; 
Maurina-Brunker, J.; Rosson, R.; Noel, J. P.; Chappell, J. Biotechnol Bioeng. 2007, 97, 
170-181. 
(85) Asadollahi, M. A.; Maury, J.; Moller, K.; Nielsen, K. F.; Schalk, M.; 
Clark, A.; Nielsen, J. Biotechnol. Bioeng. 2008, 99, 666-677. 
(86) Huang, Q. L.; Roessner, C. A.; Croteau, R.; Scott, A. I. Bioorg. Med. 
Chem. Lett. 2001, 9, 2237-2242. 
(87) Cyr, A.; Wilderman, P. R.; Determan, M; Peters, R. J. J. Am. Chem. Soc. 
2007,129, 6684-6685. 
(88) Ro, D.-K.; Paradise, E. M.; Ouellet, M.; Fisher, K. J.; Newman, K. L.; 
Ndungu, J. M.; Ho, K. A.; Eachus, R. A.; Ham, T. S.; Kirby, J.; Chang, M: C. Y.; 
Withers, S. T.; Shiba, Y.; Sarpong, R.; Keasling, J. D. Nature 2006, 440, 940-943. 
(89) DeJong, J. M.; Liu, Y.; Bollon, A. P.; Long, R. M.; Jennewein, S.; 
Williams, D.; Croteau, R. B. Biotechnol. Bioeng. 2006, 93,212-224. 
(90) Bohlmann, J.; Meyer-Gauen, G.; Croteau, R. Proc. Natl. Acad. Sci. USA 
1998, 95,4126-4133. 
(91) Richter, S.; Lamppa, G. K. Proc. Natl. Acad. Sci. USA 1998, 95, 7463-
7468. 
(92) LaFever, R. E.; Stofer Vogel, B.; Croteau, R. Arch. Biochem. Biophys. 
1994,373,139-149. 
114 
(93) Williams, D. C ; Wildung, M. R.; Jin, A. Q.; Dalai, D.; Oliver, J. S.; 
Coates, R. M.; Croteau, R. Arch. Biochem. Biophys. 2000, 379, 137-146. 
(94) Huang, K. X.; Huang, Q. L.; Wildung, M. R.; Croteau, R.; Scott, A. I. 
Protein Expr. Purif. 1998,13, 90-96. 
(95) Peters, R. J.; Flory, J. E.; Jetter, R.; Ravn, M. M.; Lee, H.-J.; Coates, R. 
M.; Croteau, R. B. Biochemistry 2000, 39, 15592 -15602. 
(96) Prisic, S.; Peters, R. J. Plant Physiol. 2007,144, 445-454. 
(97) Corey, E. J.; Matsuda, S. P. T.; Bartel, B. Proc. Natl. Acad. Sci. USA 
1993, 90, 11628-11632. 
(98) Kolesnikova, M. D.; Xiong, Q.; Lodeiro, S.; Hua, L.; Matsuda, S. P. T. 
Arch. Biochem. Biophys. 2006, 447, 87-95. 
(99) Kolesnikova, M. D.; Obermeyer, A. C; Wilson, W. K.; Lynch, D. A.; 
Xiong, Q.; Matsuda, S. P. T. Org. Lett. 2007, 9, 2183-2186. 
(100) Kolesnikova, M. D.; Wilson, W. K.; Lynch, D. A.; Obermeyer, A. C; 
Matsuda, S. P. T. Org. Lett. 2007, 9, 5223-5226. 
(.101) Xiong, Q.; Wilson, W. K.; Matsuda, S. P. T. Angew. Chem. Int. Ed. Engl. 
2006, 45, 1285-1288. 
(102) Lodeiro, S.; Xiong, Q.; Wilson, W. K.; Kolesnikova, M. D.; Onak, C ; 
Matsuda, S. P. T. J. Am. Chem. Soc. 2007,129,11213-11222. 
(103) Shan, H.; Segura, M. J. R.; Wilson, W. K.; Lodeiro, S.; Matsuda, S. P. T. 
J. Am. Chem. Soc. 2005,127, 18008-18009. 
(104) Kirby, J.; Romanini, D. W.; Paradise, E. M; Keasling, J. D. FEBSJ. 2008, 
275, 1852-1859. 
115 
(105) Hedden, P.; Phillips, A. L. Trends Plant Sci. 2000, 5, 523-530. 
(106) Wani, M. C; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T. J. 
Am. Chem. Soc. 1971, 93, 2325-2327. 
(107) Robinson, D. R.; West, C. A. Biochemistry 1970, 9, 70-79. 
(108) Robinson, D. R.; West, C. A. Biochemistry 1970, 9, 80-89. 
(109) Hill, A. M.; Cane, D. E.; Mau, J. D.; West, C. A. Arch. Biochem. Biophys. 
1996,536,283-289. 
(110) Jennewein, S.; Park, H.; DeJong, J.M.; Long, R. M.; Bollon, A. P.; 
Groteau, R. B. Biotechnol. Bioeng. 2005, 89, 588-598. 
(111) Matsuda, S. P. T.; Hart, E. A. U. S. Patent 7,238,514, 2004. 
(112) Hedden, P.; Kamiya, Y. Annu. Rev. Plant Physiol. Plant Mol. Biol. 1997, 
45,431-460. 
(113) Sun, T. P.; Kamiya, Y. Plant Cell 1994, 6, 1509-1518. 
(114) Yamaguchi, S.; Sun, T. P. K., H.; Kamiya, Y. Plant Physiol. 1998,116, 
1271-1278. 
(115) Yee, N. K. N.; Coates, R. M. J. Org. Chem. 1992, 57,4598-4608. 
(116) Barrero, A. F.; Sanchez, J. F.; Alvarez-Manzaneda, E. J.; Munoz Dorado, 
M.; Haidour, A. Phytochemistry 1993, 32, 1261-1265. 
(117) Paradise, E. M.; Kirby, J.; Chan, R.; Keasling, J. D. Biotechnol. Bioeng. 
2008,700,371-378. 
(118) Kleinig, H. Annu. Rev. Plant Physiol. Plant Mol. Biol. 1989, 40, 39-59. 
(119) Schiestl, R. H.; Gietz, R. D. Curr. Genet. 1989,16, 339-346. 
116 
(120) Corey, E. J.; Matsuda, S. P. T.; Baker, C. H.; Ting, A. Y.; Cheng, H. 
Biochem. Biophys. Res. Commun. 1996,219, 327-331. 
(121) Gonzalez, A. G.; Fraga, B. N.; Hernandez, M. G.; Hanson, J. R. 
Phytochemistry 1981, 20, 846-847. 
(122) Dudley, M. W.; Dueber, M. T.; West, C. A. Plant Physiol. 1986, 81, 335-
342. 
(123) Moore, T. C ; Coolbaugh, R. C. Phytochemistry 1976,15, 1241-1247. 
(124) Railton, I. D.; Fellows, B.; West, C. A. Phytochemistry 1984, 23, 1261-
1267. 
(125) Smith, M. W.; Yamaguchi, S.; Ait-Ali, T.; Kamiya, Y. Plant Physiol. 
1998,7/5,1411-1419. 
(126) Stofer Vogel, B.; Wildung, M. R.; Vogel, G.; Croteau, R. J. Biol. Chem. 
1996, 271, 23262-23268. 
(127) Mau, C. J.; West, C. A. Proc. Natl. Acad. Sci. USA 1994, 91, 8497-8501. 
(128) von Heijne, G.; Stepphun, J.; Herrmann, R. G. Eur. J. Biochem. 1989,180, 
535-545. 
(129) Keegstra, K.; Olsen, L. J. Annu. Rev. Plant Physiol. Plant Mol. Biol. 1989, 
40,471-501. 
(130) Richter, S.; Lamppa, G. K. J. Cell. Biol. 1999,147, 33-43. 
(131) Takahashi, S.; Yeo, Y.-S.; Zhao, Y.; O'Maille, P. E.; Greenhagen, B. T.; 
Noel, J. P.; Coates, R. M.; Chappell, J. J. Biol. Chem. 2007, 282, 31744-31754. 
(132) Millis, J. R.; Saucy, G. G.; Maurina-Brunker, J.; McMullin, T. W.; PCT. 
Int. Appl, 2000. 
117 
(133) Whitesides, G. M.; Lewis, D. W. J. Am. Chem. Soc. 1970, 92, 6979-6980. 
(134) Wilson, W. K.; Scallen, T. J.; Morrow, C. J. J. Lipid Res. 1982, 23, 645-
652. 
(135) Bouwmeester, H. J.; Verstappen, F. W. A.; Posthumus, M. A.; Dicke, M. 
Plant Physiol. 1999,121,173-180. 
(136) Degenhardt, J.; Gershenzon, J. Planta 2000,210, 815-822. 
(137) Schnee, C ; Kollner, T. G.; Gershenzon, J.; Degenhardt, J. Plant Physiol. 
2002,130,2049-2060. 
(138) Poulter, C. D.; Rilling, H. C. Biochemistry 1976,15, 1079-1083. 
(139) Carrau, F. M.; Medina, K.; Boido, E.; Farina, L.; Gaggero, C; Dellacassa, 
E.; Versini, G.; Henschke, P. A. FEMS Microbiol. Lett. 2005, 243, 107-115. 
(140) Benedict, C. R.; Lu, J.-L.; Pettigrew, D. W.; Liu, J.; Stipanovic, R. D.; 
Williams, H. J. Plant Physiol. 2001,125, 1755-1765. 
(141) Farnesal mass spectrum obtained from Wiley Subscription Services, Inc. 
through SciFinder Scholar, 2008. 
(142) Cornwell, P. A.; Barry, B. W. J. Pharm. Pharmacol. 1994, 46, 261-269. 
(143) Yamane, M. A.; Williams, A. C; Barry, B. W. J. Pharm. Pharmacol. 
1995, 47, 978-989. 
(144) Kubo, I.; Muroi, H.; Himejima, M. J. Agric. Food Chem. 1992, 40, 245-
248. 
(145) Kubo, I.; Morimitsu, Y. J. Agric. Food Chem. 1995, 43, 1626-1628. 
(146) Lopes, N. P.; Kato, M. J.; Andrade, E. H.; Maia, J. G.; Yoshida, M.; 
Plancart, A. R.; Katzin, A. M. J. Ethnopharmacol. 1999, 67, 313-319. 
118 
(147) Arruda, D. C ; D'Alexandri, F. L.; Katzin, A. M.; Uliana, S. R. B. 
Antimicrob. Agents Chemother. 2005, 49, 1679-1687. 
(148) Lee, S. J.; Han, J. I.; Lee, G. S.; Park, M. J.; Choi, I. G.; Na, K. J.; Jeung, 
E. B. Biol. Pharm. Bull. 2007, 30, 184-188. 
(149) Lindahl, A.-L.; Olsson, M. E.; Mercke, P.; Tollbom, O.; Schelin, J.; 
Brodelius, M.; Brodelius, P. E. Biotechnology Lett. 2005, 28, 571-580. 
(150) Jackson, B. E.; Ph. D. Thesis, Rice University, 2004. 
(151) Schwartz, M. A.; Swanson, G. C. J. Org. Chem. 1979, 44, 953-958. 
(152) Xu, R.; Fazio, G. C ; Matsuda, S. P. T. Phytochemistry 2004, 65, 261-290. 
(153) Fazio, G. C ; Xu, R.; Matsuda, S. P. T. J. Am. Chem. Soc. 2004,126, 
5678-5679. 
(154) Adams, B. G. J. Bacteriol. 1972, 111, 308-315. 
(155) Fazio, G. C.; Ph. D. Thesis, Rice University, 2006. 
(156) De Pascual Teresa, J.; Urones, J. G.; Marcos, I. S.; Basabe, P.; Sexmero 
Cuadrado, M. J.; Fernandez Moro, R. Phytochemistry 1987, 26,1767-1776. 
(157) Delia Greca, M.; Fiorentino, A.; Monaco, P.; Previtera, L. Phytochemistry 
1994,35,1017-1022. 
(158) Xiang, T.; Shibuya, M.; Katsube, Y.; Tsutsumi, T.; Otsuka, M.; Zhang, H.; 
Masuda, K.; Ebizuka, Y. Org. Lett. 2006, 8, 2835-2838. 
(159) Xiang, T.; Shibuya, M.; Katsube, Y.; Tsutsumi, T.; Otsuka, M.; Zhang, H.; 
Masuda, K.; Ebizuka, Y. Org. Lett. 2006, 8, 2835-2838. 
(160) Panini, S. R.; Sexton, R. C ; Gupta, A. K.; Parish, E. J.; Chitrakorn, S.; 
Rudney, H. J. Lipid Res. 1986, 27, 1190-1204. 
119 
(161) Casey, W. M.; Burgess, J. P.; Parks, L. W. Biochim. Biophys. Acta 1991, 
1081, 279-284. 
(162) Parish, E. J.; Parish, S. C ; Li, S. Crit. Rev. Biochem. Mol. Biol. 1999, 34, 
265-272. 
(163) Ausubel, F. M.; Brent, R.; Kingston, R. E.; Moore, D. D.; Seidman, J. G.; 
Smith, J. A.; Struhl, K., Eds. Current Protocols in Molecular Biology; Wiley-
Interscience: New York, 1999. 
Appendix A - List of abbreviations 
A. grandis Abies grandis 
AgAS Abies grandis abietadiene synthase 
Ala alanine 
Amp ampicillin 
Asn asparagine 
AtGAl Arabidopsis thaliana enf-copalyl pyrophosphate synthase 
AtGA2 Arabidopsis thaliana ent-kaurene synthase 
ATP adenosine 5'-triphosphate 
BHT butylated hydroxytoluene 
BiGal bi-directional galactose promoter 
BSA bovine serum albumin 
B STF A bis(trimethylsily l)trifluoroacetamide 
CDCI3 deuterated chloroform 
cDNA complementary deoxyribonucleic acid 
COSYDEC decoupled ' H - ' H correlation NMR spectroscopy 
CPE chloroplast processing enzyme 
D dextrose 
DEPT 
diH20 
DMAPP 
DMSO 
distortionless enhancement by polarization transfer 
distilled water 
dimethylallyl pyrophosphate 
dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTPs deoxynucleosides-5'-triphosphates 
DOS dioxidosqualene 
DPP1 diacylglycerol pyrophosphate phosphatase 
E. coli Escherichia coli 
El unimolecular elimination 
E2 bimolecular elimination 
EDTA ethylene diamine tetraacetic acid 
Epi epicoprostanol 
ER endoplasmic reticulum 
EtOH ethanol 
Eu(hfc)3 europium tris[2-(heptafluoropropylhydroxymethylene)-(+)-camphorate] 
FAD flavin adenine dinucleotide 
FPP farnesyl pyrophosphate 
G galactose 
GC-FID gas chromatography-flame ionization detection 
GC-MS gas chromatography-mass spectrometry 
GGPP geranylgeranyl pyrophosphate 
Gin glutamine 
Glu glutamic acid, glutamate 
Gly glycine 
GPP geranyl pyrophosphate 
GTAE 40 mM Tris-base, 20 mM acetic acid, 1 mM EDTA, 1 mM guanosine 
Heme 
HMBC 
HMG-CoA 
IPP 
KanMX 
LB 
Leu 
LPP1 
m/z 
MOPS 
mqH20 
mRNA 
NAD(P)H 
NCBI 
NMR 
NSL 
OD6oo 
OS 
osc 
PCR 
PEG 
Phe 
PIPES 
hemin chloride 
heteronuclear multiple bond correlation 
3-hydroxy-3-methylglutaryl-coenzyme A 
isopentenyl pyrophosphate 
geneticin-resistant marker 
Luria-Bertani 
leucine 
lipid phosphate phosphatase 
mass-to-charge ratio 
3 - [N-morpholino]propanesulfonic acid 
milli-Q filtered water 
messenger ribonucleic acid 
nicotinamide adenine dinucleotide (phosphate) 
National Center for Biotechnology Information 
nuclear magnetic resonance 
non-saponifiable lipids 
optical density measured at 600 nm 
oxidosqualene 
oxidosqualene cyclase 
polymerase chain reaction 
polyethylene glycol 
phenylalanine 
1,4-piperazinethanesulfonic acid 
PtDS Pisum sativa putative diterpene synthase 
RnaseA ribonuclease A 
RT-PCR reverse transcriptase polymerase chain reaction 
S. cerevisiae Saccharomyces cerevisiae 
SC synthetic complete 
SDS sodium dodecyl sulfate 
Ser serine 
SNI unimolecular substitution 
SN2 bimolecular substitution 
SrGAl Stevia rebaudiana e«/-copalyl pyrophosphate synthase 
SrGA2 Stevia rebaudiana e/rt-kaurene synthase 
ssDNA single-stranded DNA 
TAE 40 mM Tris-base, 20 mM acetic acid, 1 mM EDTA 
TbTS Taxus brevifolia taxadiene synthase 
TLC thin-layer chromatography 
TMS tetramethylsilane (for NMR) or trimethylsilyl (for derealization) 
TMS-epi TMS-derivatized epicoprostanol 
trHMGl truncated hydroxymethylglutaryl-coenzyme A reductase 
Tris-HCl tris(hydroxymethyl)aminomethane hydrochloride 
Trp tryptophan 
U or Ura uracil 
UV ultraviolet 
YP yeast extract plus peptone 
Appendix B - Relevant S. cerevisiae enzymes 
BTSl geranylgeranyl pyrophosphate synthase 
DPP1 diacylglycerol pyrophosphate phosphatase 
ERG1 squalene epoxidase 
ERG 10 acetoacetyl-Co A thiolase 
ERG 12 mevalonate kinase 
ERG13 HMG-CoA synthase 
ERG 19 mevalonate-5 -pyrophosphate decarboxylase 
ERG20 farnesyl pyrophosphate synthase 
ERG7 lanosterol synthase 
ERG8 phosphomevalonate kinase 
ERG9 squalene synthase 
HMGR HMG-CoA reducase 
IDI1 isopentenyl pyrophosphate isomerase 
LPP1 lipid phosphate phosphatase 
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Appendix C - List of Relevant Plasmids and Yeast Strains 
Plasmids 
pCVP2.1 A. thaliana e«/-copalyl pyrophosphate synthase (GA1) in 
pRS426GalR subcloned at Sal I-Not I 
pCVP6.1 A. thaliana ew/-kaurene synthase (GA2) in pRS313biGal subcloned 
at Xba I-BamH I 
pCVP26.1 A. thaliana GA1 and GA2 in pRS426biGal subcloned at Sac II -
Not I (AtGAl) and^&a I-BamHI (AtGA2) 
pAMB5.3 A. thaliana chloroplast processing enzyme in pRS313Gal 
subcloned at Sal I - Not I 
pEH9.0 Abies grandis abietadiene synthase in pRS426Gal subcloned at 
BamHI- NotI 
pEH12.4 S. cerevisiae truncated HMG-CoA reductase (trHMGl) in 
pRS305biGal subcloned at BamH I - Not I 
pGCF6.0 S. cerevisiae squalene epoxidase (ERG1) in pRS305Gal subcloned 
at Sal I -Not I 
Yeast strains 
EHY18 upc2-l incorporated, trHMGl under control of GAL 1 promoter, 
GGPP synthase under control of GAL 1 promoter 
(MATapGALl-BTSl::hispGALl-trHMGl::LEU2 upc2-l uraS-52 
trpl-A63 leu2-3,112 his3-A200 ade2 Gaf) 
126 
CPY1 upc2-l incorporated, trHMGl under control of GAL 1 promoter, 
GGPP synthase under control of GAL 1 promoter, AtGAl under 
control of Gal 10 promoter 
(MAT*
 PGAL10-AtGAl::URA3 pGALl-BTSl::his pGALl-
trHMGl::LEU2 upc2-l ura3-52 trpl-A63 leu2-3,112 his3-A200 
ade2 Gal^) 
CPY2 upc2-l incorporated, trHMGl under control of GAL 1 promoter, 
GGPP synthase under control of GAL 1 promoter, AtGAl under 
control of Gal 10 promoter, ^GA2 under control of GAL 1 
promoter 
(MATu
 PGAL10-AtGAl::URA3 pGALl-AtGA2::HIS3 pGALl-
BTSl::his pGALl-trHMGl::LEU2 upc2-l ura3-52 trpl-A63 leu2-
3,112 his3-A200 ade2 Gal+) 
PMY1 heme auxotroph, squalene synthase deletion, trHMGl under 
control of GAL 1 promoter 
(MAT*
 PGALl-trHMGl::LEU2 erg9::HIS3 heml::TRPl ura3-52 
trpl-A63 Ieu2-3,U2 his3-A200 ade2 Gal") 
PMY2 heme auxotroph, squalene synthase deletion, trHMGl under 
control of GAL 1 promoter, 
(MATH
 PGALl-trHMGl::LEU2 erg9::HIS3 hemlr.TRPl ura3-52 
trpl-A63 leu2-3,112 his3-A200 ade2 Gal4) 
BEJY14 heme auxotroph, squalene synthase deletion, trHMGl under 
control of GAL 1 promoter, 
127 
(MAT*
 PGALl-trHMGl::LEU2 erg9::HIS3 heml::TRPl ura3-52 
trpl-A63 leu2-3,112 his3-A200 ade2 Gaf) 
SMY8 heme auxotroph, lanosterol synthase deletion 
(MAT* erg7::HIS3 heml::TRPl ura3-52 trpl-A63 leu2-3,112 
his3-A200 ade2 Gaf) 
ABY1 heme auxotroph, lanosterol synthase deletion, trHMGl under 
control of GAL 1 promoter 
(MAT* pGALl-trHMGl::LEU2 erg7::H!S3 heml::TRPl ura3-52 
trpl-A63 leu2-3,112 his3-A200 ade2 Gal+) 
ABY2 heme auxotroph, lanosterol synthase deletion, ScERGl under 
control of GAL 1 promoter 
{MATa.
 PGAL1-ERG1::LEU2 erg7::HIS3 heml::TRPl ura3-52 
trpl-A63 leu2-3,112 his3-A200 ade2 Gaf) 
Appendix D - Spectral data 
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Figure D.l. Electron impact mass spectrum (EI-MS) of geranylgeraniol isolated from 
EHY18[pRS426Gal] crude NSL. The mass spectral pattern matches that of an authentic 
geranylgeraniol standard. 
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Figure D.2. EI-MS of geranyllinalool isolated from an EHY18[pRS426Gal] crude NSL. 
The mass spectral pattern matches that of an authentic geranyllinalool standard. 
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Figure D.3. Mass spectrum of en^-copalol from a crude NSL of CPY1. 
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Figure D.4. Mass spectrum of e«?-manool/e«M3-epimanool from a CPY1 crude NSL. 
60000 
500004 
c 400001 
CO 
T3 
C 
< 30000 
20000{ 
100004 
69 
91 
!)j^ 
109 
125 
147 
163 1 ? 7 
kJi lu^ 
213 
"(-"f 
257 
229 
' vri'vpi 
272 
60 80 100 120 140 160 180 200 220 240 260 
m/z-> 
Figure D.5. EI-MS of e«/-kaurene isolated from a CPY2 crude NSL. 
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Figure D.6. *H and ,3C NMR chemical shift assignments for e«/-kaurene. 
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Figure D.7. EI-MS of a-bisabolol. Spectrum A is an authentic standard, and spectrum B 
is a-bisabolol from PMYl[pRS316Gal]. 
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Figure D.8. Farnesal mass spectrum. Spectrum A is from literature, and spectrum B was 
isolated from PMYl[pRS316Gal]. 
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Figure D.9. Mass spectrum of farnesyl acetate. Spectrum A is that of an authentic 
standard and spectrum B is from PMYl[pRS316Gal]. 
